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Abstract 
 
It has now been demonstrated that the μ, δ1, δ2 and κ1 opioid receptor agonists 
represent the most promising group of opioids for the creation of drugs enhancing cardiac 
tolerance to the detrimental effects of ischemia/reperfusion. Opioids are able to prevent 
necrosis and apoptosis of cardiomyocytes during ischemia/reperfusion and improve cardiac 
contractility in the reperfusion period. The opioid receptor agonists exert an infarct-reducing 
effect with prophylactic administration and prevent reperfusion-induced cardiomyocyte death 
when ischemic injury of heart has already occurred; i.e. opioids can mimic preconditioning 
and postconditioning phenomena. Furthermore, opioids are also effective in preventing 
ischemia-induced arrhythmias.  
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1. Historical Background 
The main cardiac manifestations of ischemia/reperfusion (I/R) are necrosis, apoptosis 
of cardiomyocytes, contractile dysfunction, and ventricular arrhythmias.1-4 In the seventies it 
was clear that the prognosis for patients who had suffered acute myocardial infarction was 
highly dependent on the amount of ventricular muscle that was lost to infarction. Although it 
was proposed that an intervention that could reduce infarct size would save lives, there was 
great debate as to whether therapeutic attenuation of these negative manifestations of 
myocardial ischemia was even possible. This argument was settled once and for all in 1986, 
when three American researchers discovered the phenomenon of ischemic preconditioning 
(IP).5 They found that exposure to 4 brief periods of I/R causes the heart to become very 
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resistant to infarction from a subsequent prolonged ischemic insult. The protective effect of IP 
is maintained only for 2 – 3 hr making it impractical for any clinical application. However, a 
day later these hearts again became resistant to infarction, this time lasting about 4 days. This 
has been variously called “delayed preconditioning”, “late preconditioning”, or “second 
window of protection”.6  Still the major impediment to translating preconditioning to a 
clinical setting was the requirement that it has to be instituted prior to the onset of ischemia. 
Pretreatment is impossible, however, in the setting of acute myocardial infarction.   
Although the mechanism of IP was obscure, it was strongly believed that it must target 
injury during ischemia and that the pretreatment requisite was absolute. It took another 17 
years after the discovery of IP before it was realized that IP actually prevents reperfusion 
injury and treatment could be instituted right up to the time of reperfusion. In 2003, Vinten-
Johansen’s group discovered “ischemic postconditioning” (IPost). It turned out that 3 cycles 
of very brief reperfusion/ischemia cycles after a prolonged ischemic insult greatly decrease 
the fraction of the ischemic myocardium that infarcted, often called the “infarct size-area at 
risk ratio” (IS/AAR).7 This seminal discovery finally opened the door to clinical application 
but while IPost was theoretically possible in patients whose coronary thrombus was removed 
with angioplasty, it proved to be surprisingly awkward in many cases. A postconditioning 
drug would be a great improvement.  
The mechanism of IP had been obscure until it was discovered that it resulted from 
protective signal transduction pathways triggered by Gi-coupled plasma membrane receptors.8  
These investigators found that adenosine was a trigger through adenosine A1 receptors but 
soon if was found that other Gi-coupled receptors also participated in triggering IP’s 
protection. In 1995, Gross’s group obtained data that the infarct-reducing effect of IP was lost 
after blocking opioid receptors (ORs) with naloxone9 and a year later they reported that they 
could precondition the heart with morphine.10 Kin et al.11 demonstrated that ORs were also 
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involved in IPost when they showed that naloxone 5 min before reperfusion abolishes the 
infarct-sparing effect of IPost. 
IP or IPost with ischemia is impractical in the clinical setting. The foregoing studies 
generated enormous interest by physiologists and pharmacologists and provided the impetus 
for research aimed at finding pharmaceutical OR agonists which could mimic the 
phenomenon of IP and IPost. In this review, we evaluate the effect of various OR ligands on 
the necrosis and apoptosis of cardiomyocytes, myocardial stunning, and the incidence of 
ischemic and reperfusion arrhythmias. To aid the reader we have included Table 1 which lists 
all of the OR agonists and antagonists discussed in this review. 
2. Localization of opioid receptors involved in regulation of heart function  
A. Opioid receptors in the central nervous system 
It is well known that all discovered mammalian opioid peptides have been isolated 
from brain where they are most abundant12 and it is not surprising that the brain and spinal 
cord have a high density of ORs.13-21 μ OR were discovered in the spinal cord, in the 
periaqueductal grey matter (PAG), nucleus accumbens, amygdala and in several thalamic 
nuclei.15, 19 Transcripts of μ OR were found in the prefrontal cortex, nucleus accumbens, 
caudate putamen and thalamus.20 δ OR was identified in spinal cord,16 caudate putamen, 
nucleus accumbens and olfactory tubercle.18 Transcripts of δ OR were detected in the 
prefrontal cortex, nucleus accumbens, caudate putamen.20 The κ OR was found in spinal 
cord.16 Transcripts for this receptor were identified in nucleus accumbens, caudate putamen, 
preoptic area and hypothalamus.20 κ OR were also found in the prefrontal cortex, nucleus 
accumbens, hypothalamus, amygdala, ventral tegmental area, dorsal raphe nucleus, and locus 
coeruleus.21 The ORL1 receptor or nociceptin/orphanin FQ (N/OFQ) opioid peptide receptor 
(NOPr) was found in several rat brain areas, including the cerebral cortex, thalamus, subforn 
ical organ, habenula, hypothalamus, central gray, dorsal raphe, locus coeruleus hippocampus, 
5 
 
Cardioprotective Properties of Opioid Receptor Agonists 
amygdala, caudate nucleus, putamen, medial thalamic nuclei and the dorsal horn of the spinal 
cord.14,17  
Most of opioid peptides do not penetrate the blood-brain barrier so their effects, when 
administered intravenously, are associated with activation of peripheral ORs.22-24 However, 
the non-peptide OR agonists can enter the brain and activate ORs in autonomic centers 
regulating the functional state of the heart. It has been shown that perfusion of the fourth 
cerebral ventricle with the selective peptide μ OR agonist FK 33-824 induces bradycardia in 
the conscious dogs.25 In anesthetized dogs, [D-Met2,Pro5]enkephalinamide perfusion through 
the cerebroventricular system elicited bradycardia, which was accompanied by an increase in 
the vagal discharge rate.26 It has been shown that intracisternal administration of opioid 
peptides also evoked bradycardia in unanaesthetized dogs.27 This effect was abolished by 
pretreatment with atropine. It has also been found that intracerebroventricular administration 
of the selective μ OR agonist DAMGO or the selective δ OR agonist DPDPE increased 
plasma catecholamine levels and blood pressure in conscious rats.28 However DAMGO 
appeared to be a more potent regulator of the catecholamine level than DPDPE. At a dose of 5 
nM and higher, DAMGO induced bradycardia mediated by vagal activation. The authors 
concluded that brain ORs regulating autonomic outflow, cardiovascular and respiratory 
function are mainly of the μ type, although a δ opioid system may also contribute to 
sympathoadrenal and respiratory effects of opioids.  
Thus, presented data indicate that ORs are present in the brain regions responsible for 
the regulation of function of the cardiovascular system and the stress response to strong 
stimuli.  
B. Opioid receptors in the heart 
All three OR (μ, δ, κ) transcripts were also detected in several peripheral tissues 
including the intestine, adrenal, kidney and lung.29 In the stomach, δ OR and κ OR but not μ 
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OR transcripts were found.29 mRNAs for opioid precursors were detected in adrenocortical 
cells.30 It has been established that μ and κ OR agonists can regulate cortisol and aldosterone 
secretion from the adrenocortical cells.30 The δ OR was found in a PC12 cell line derived 
from a pheochromocytoma of the rat adrenal medulla.31 Changes in function of these organs 
by activation of their ORs may indirectly affect the heart’s function.  
The first report reporting the existence of ORs in the myocardium was published in 
1981.32 In 1988, the existence of δ OR in the myocardium was demonstrated  using a 
radioligand binding assay.33 The next year, δ and κ ORs were also found in rat cardiac 
sarcolemma using this method.34 Later other investigators35 confirmed the existence of κ1 OR 
in the myocardium.36 Opioid-binding sites in the myocardium were also confirmed in other 
studies.37,38 In 1996, transcripts of δ and κ ORs were found in the heart.29 These data were 
later confirmed by Weil et al.39 None of these studies detected the μ OR in cardiomyocytes. 
However, in 1995, the μ3 subtype of this receptor () was detected in the coronary 
microvascular’s endothelial cells.40 This group of researchers also established that endothelial 
cells express a δ2 OR subtype.41 Vascular smooth muscle cells also appeared to express δ 
OR.42 Dumont and Lemaire were able to detect and characterize a high affinity [3H]nociceptin 
binding site in the membrane preparations of rat heart.43 Kim et al. confirmed the existence of 
the ORL1 receptor in cardiac myocytes.44 Thus, the view was formed that cardiac myocytes 
express δ OR, κ OR and ORL1 receptor but not μ OR. This opinion was changed in 2005 
when Head et al. found μ OR on the sarcolemma of cardiomyocytes using 
immunofluorescence microscopy.45 μ-OR mRNA was also identified in the human right 
atrium. However, the amount of this receptor’s mRNA in cardiomyocytes was significantly 
lower than the ORL1 mRNA content.46 Later, μ, δ and κ ORs were detected 
immunohistochemically in human heart.47 The researchers found that μ and δ ORs are located 
mainly in cardiomyocytes as well as on sparse individual nerve fibers. Likewise, κ OR was 
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identified predominantly in cardiomyocytes. This receptor was also found on intrinsic cardiac 
adrenergic cells. It has been established that the δ OR is co-localized with the sensory neuron 
marker calcitonin gene-related peptide (CGRP).47 Previously, similar data were obtained by 
Mousa et al. They identified μ OR and κ OR mRNA, as well as other OR proteins on cardiac 
parasympathetic, sympathetic, and sensory neurons.48 δ ORs were detected in the cholinergic 
neurons, small intensely fluorescent (SIF) catecholaminergic cells, afferent nerve terminals, 
and atrial cardiomyocytes.49 
Thus, all four types of ORs (μ, δ, κ and ORL1) have been found in cardiomyocytes. δ 
OR, κ OR and ORL1 receptor appeared to have the highest density in cardiomyocytes. μ and 
δ ORs are present in the endothelial cells and vascular smooth muscle cells express δ OR. 
ORs have been detected on the sensory nerve terminal, on intrinsic cardiac adrenergic cells 
and are probably present in the sympathetic and parasympathetic terminals in the heart. It is 
safe to assume that activation of any of these receptors may potentially affect the functional 
state of the heart. 
Intrinsic cardiac adrenergic (ICA) cells were identified in rodent and human heart by 
Huang et al.50 In 2007, they discovered localization of δ OR immunoreactivity in ICA cells in 
human and rat hearts.51 They demonstrated that the selective δ1 OR agonist DPDPE enhanced 
epinephrine51 and CGRP release52 from ICA cells in denervated rat heart and these effects 
were abolished by the β-adrenergic and CGRP receptor inhibitors. The authors suggested that 
the cardiotropic effects of δ OR agonists are mediated through β2-AR/CGRP signaling.  
C. Opioid receptors modulate neural control of the heart 
Opioid peptides can alter the autonomic nervous regulation of the heart function. 
Indeed, Kett et al. established that intravenous administration of H-Tyr-D-Arg-Phe-Lys-NH2 
(DALDA), a selective peptide μ OR agonist which does not penetrate the blood-brain barrier, 
blunted norepinephrine-induced baroreflex bradycardia but had no effect on the sodium 
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nitroprusside-evoked tachycardia.53 Pretreatment with naloxone methiodide, a peripheral OR 
antagonist, abolished DALDA-induced suppression of baroreflex. These data indicate that 
DALDA inhibits the baroreflex through peripheral OR occupancy. Later, these investigators 
established that the selective peptide μ OR agonist D-Ala2,N-Me-Phe4,Gly5-ol (DAMGO) 
suppresses baroreflex-mediated bradycardia in the awake sheep but the selective κ OR agonist 
U50,488 had no such effect.54 Peripheral μ OR stimulation can suppress vagus-mediated 
baroreflex and it can be assumed that these ORs are located in the nerve endings innervating 
the sinoatrial node. 
Urthaler et al. established that selective perfusion of the sinus node with morphine in 
anesthetized dogs evokes bradycardia.55 Bradycardia was not altered by atropine or vagotomy 
and intranodal administration of morphine had no effect on the acceleration of heart rhythm 
produced by stellate ganglion stimulation or by selective perfusion of the sinus node with 
norepinephrine. The authors concluded that morphine-evoked bradycardia was autonomic 
nervous system independent and a direct effect of morphine on the sinoatrial node cells. 
These results were confirmed by the data of Gautret and Schmitt.56 They found that an 
intravenous administration of ethylketocyclazocine, a preferential κ OR agonist, induced a fall 
in heart rate and blood pressure (BP) in rats anaesthetized with pentobarbital. The bradycardia 
and the hypotension were not altered by bilateral vagotomy and atropine, but were completely 
eliminated by naloxone and Mr 2266, a preferential κ OR antagonist. Ethylketocyclazocine-
induced bradycardia persisted in β-adrenoreceptor-blocked and pithed rats.56 These results 
indicate that peripheral κ OR located in the heart’s conduction system can affect cardiac 
rhythm. 
However, other data indicate that opioids can exhibit vagolytic effect. The nervi vagi 
of isolated perfused rabbit heart were electrically stimulated and morphine, a preferential μ 
OR agonist, met-enkephalin, μ OR and δ OR agonist, and D-Ala2,D-Leu5-enkephalin 
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(DADLE), a preferential δ OR agonist, reduced the vagal bradycardia with IC50 values of 148, 
25 and 3.2 nM, respectively. Pretreatment with naloxone abolished the vagolytic effect of all 
opioids. The selective δ OR antagonist ICI 174864 eliminated met-enkephalin effect but did 
not antagonize morphine’s action.57 These data indicate that stimulation of both μ OR and δ 
OR can attenuate vagus-mediated bradycardia but stimulation of presynaptic δ OR have a 
more powerful vagolytic effect. Similar data were obtained by Musha et al. in the experiments 
on anesthetized dogs with electrical stimulation of n. vagus.58 They confirmed that 
presynaptic δ OR activation prevents vagal bradycardia. In pithed rats pretreated with 
propranolol, vagal stimulation or injection of methacholine decreased heart rate (HR).59 The 
selective ORL1 receptor agonist nociceptin (orphanin FQ) decreased the vagal bradycardia 
but did not modify the methacholine-induced decrease in HR. The selective ORL1 receptor 
antagonist [Phe1ψ(CH2-NH)Gly2]-nociceptin(1-13)NH2 antagonized vagolytic effect of 
nociceptin. Authors concluded that orphanin FQ prevents vagal bradycardia acting on the 
presynaptic ORL1 receptor located on the vagal terminal in the heart.59 It was established that 
MEAP (met-enkephalin-Arg-Phe) and the selective δ2 OR agonist deltorphin II suppressed 
vagal bradycardia when they were delivered directly into the sinoatrial node by local 
microdialysis.60 The authors also found that δ OR stimulation only in the sinoatrial node 
prevents vagal bradycardia. In the further study, they conducted a comparative analysis of the 
ability of δ OR agonists to suppress vagal bradycardia during administration into the sinoatrial 
node and found that the vagolytic effect of opioids is mediated by δ2 ORs in the sinoatrial 
node.61 These data were confirmed in a subsequent study by the same group.62 They later 
established that δ2 ORs are located on the cholinergic vagal terminals in the sinoatrial node.63  
Opioids can modulate not only the vagal discharge rate but also sympathetic outflow. 
Ledda and Mantelli using isolated guinea-pig atria discovered that the non-selective OR 
agonist etorphine inhibits the sympathetic response induced by direct electical stimulation.64 
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Pretreatment with naloxone abolished this effect of etorphine. However, etorphine did not 
affect an inotropic effect of norepinephrine. Authors concluded that etorphine stimulates 
presynaptic inhibitory ORs on adrenergic nerve terminals in the heart. Later they established 
that the inhibitory effect of the opioid peptides could be due to stimulation of presynaptic 
inhibitory δ and κ ORs on adrenergic nerve terminals in the heart.65, 66 Somewhat different 
results were obtained by Starke et al.67 In their study using selective OR agonists and 
antagonists they found that, under in vitro conditions, only presynaptic κ ORs but not μ ORs 
or δ ORs inhibit the norepinephrine release from the sympathetic nervous innervating the 
rabbit heart. Fuder published results of experiments where isolated guinea-pig atria were 
loaded with 3H-(-)-norepinephrine. In these experiments, the intrinsic nerves stimulation 
evoked norepinephrine efflux.68 They discovered that the non-selective OR agonist etorphine, 
the κ OR agonists ethylketocyclazocine, dynorphin A (1-13) and the δ OR agonist DADLE 
but not the preferential μ OR agonist morphine inhibit the stimulation-induced norepinephrine 
efflux in a concentration-dependent manner. The inhibitory effect of ethylketocyclazocine and 
etorphine was antagonized by naloxone. The authors hypothesized that activation of 
presynaptic κ ORs and apparently δ ORs inhibits norepinephrine release from sympathetic 
nerves in the heart.68 Others showed that a strong inhibition of on the sympathetic-mediated 
positive inotropic effect evoked by electrical field stimulation of guinea-pig atria can be 
achieved by κ OR agonists U-50488 and U-69593, whereas δ OR agonists, DPDPE and 
BW373U86 were ineffective. This effect of κ OR agonists was reversed by the selective κ OR 
antagonist nor-binaltorphimine.69 
Similar data were obtained in the in vivo experiments on pithed animals. Thus in 
pithed rabbits, it was found that ethylketocyclazocine decreased blood pressure (BP), the 
endogenous plasma norepinephrine level and the 3H-norepinephrine release rate.70 These 
effects were inhibited by naloxone. Investigators concluded that ethylketocyclazocine inhibits 
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norepinephrine release from postganglionic sympathetic neurons, apparently by stimulation of 
ORs at the terminal axons. Later they established that the preferential κ2 OR agonist 
bremazocine prevents the 3H-norepinephrine release and BP elevation in response to 
electrically (2 Hz) stimulated sympathetic outflow in pithed rabbits but has no effect on the 
BP increase evoked by an intravenous infusion of norepinephrine.71 The inhibitory effects of 
bremazocine was antagonized by naloxone. These results indicate that the κ2 OR stimulation 
inhibits norepinephrine release and consequently lowers BP by activation of peripheral, 
probably prejunctional, κ OR. This function of κ OR was later confirmed in the experiments 
of Caffrey’s group72 whilst Feuerstein et al. excluded a possible role of μ OR in the regulation 
of sympathetic outflow in pithed rats.73 Malinowska et al. showed in the experiments on 
pithed rats pretreated with atropine that the postganglionic sympathetic nerves innervating the 
rat heart have presynaptic ORL1 receptor and its activation inhibits the sympathetic outflow.59 
Thus, the data show that activation of peripheral ORs can inhibit the cardiotropic effects of 
parasympathetic and sympathetic nerve stimulation. However, in the conscious animals the 
effect of opioid peptides can be quite the opposite. In particular, it has been shown that in 
unanesthetized sheep and dogs, intravenous administration of enkephalins or nociceptin may 
cause transient rise in BP and HR associated with enhanced sympathetic outflow.74.75,76 These 
effects were associated with activation of ORs located outside the blood-brain barrier in the 
area postrema, a blood-brain barrier-deficient small, elevated area in the lateral wall of the 
inferior recess of the fourth ventricle.74-76 It was established that stimulation of central μ and δ 
OR also can increase plasma catecholamine levels and BP.12,28 
In 1990, Giuliani et al. demonstrated that electrical stimulation of the left atria of 
reserpine-pretreated guinea-pigs in the presence of atropine produces a positive inotropic 
effect involving activation of capsaicin-sensitive afferents.77 μ OR agonists dermorphin, 
DAMGO and morphine all inhibited this effect. The authors concluded that capsaicin-
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sensitive nerves in the atrium have μ OR, which inhibit transmitter release from sensory nerve 
terminals.77 In  a similar model, these investigators found that the selective ORL1 agonist 
nociceptin inhibits a positive inotropic response induced by electrical field stimulation.78 
However, nociceptin (the selective ORL1 agonist) did not affect the positive inotropic effect 
of exogenous CGRP. Therefore, the authors suggested that nociceptin inhibits CGRP release 
by activation of ORL1 receptors localized on the afferent nerve endings in atria.78  
The adrenal medulla can also be involved in the cardiovascular effects of opioids. 
Gulati and Bhargava studied cardiovascular effects of intravenous administration of κ OR 
agonists bremazocine, tifluadom and U-50,488 in anesthetized rats.79 All three opioids evoked 
bradycardia. Bremazocine and U-50,488 decreased BP. The hemodynamic effects of the 
opioids were blocked by bilateral adrenal demedullation. The peripherally acting OR 
antagonist naltrexone methylbromide blocked the cardiovascular effects of U-50,488. Based 
on these results, the investigators suggest that cardiovascular effects of κ OR agonists are 
mediated through the adrenal medulla and peripheral κ OR stimulation.79 The mechanism of 
this effect of κ OR agonists remains unknown. 
Taken together, the available experimental data suggest that the  heart is richly 
populated with ORs located on the sarcolemma of cardiomyocytes, cell membrane of ICA and 
the coronary endothelial cells. In addition they are locatedon the sympathetic and 
parasympathetic nerve terminals in the heart, in the adrenal medula and in the brain regions 
responsible for the regulation of the heart. Thus it should come as no surprise that some of 
these can exert a cardioprotective effect against ischemia/reperfusion injury. 
3. Anti-Infarct Effect of Pretreatment with Opioid Receptor Agonists  
A. δ1 opioid agonists 
Rats given 0.3 mg/kg of morphine intravenously prior to coronary artery 
occlusion/reperfusion experienced a decrease in the IS/AAR by 4.5 fold.10 A year later, the 
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same group of researchers found that the infarct-sparing effect of morphine depended upon δ 
OR activation.80 In 1998, Miki et al. reported that morphine reduced infarct size in rabbits.81 
Morphine was tested at doses of 0.3, 0.8 and 3 mg/kg but only the highest dose protected 
suggesting a species difference between ORs in rats and rabbits. Morphine also increases the 
tolerance of isolated rat cardiomyocytes to a 90-min hypoxia.82 Wu et al. 83 confirmed the 
cardioprotective properties of morphine. They administered 8 mg/kg intraperitoneally to rats. 
It was not mentioned why they selected such a high dosage but they found that morphine’s 
protection could be prevented by blocking μ, δ or κ ORs suggesting that all three OR subtypes 
seem to be involved in the cardioprotection of morphine. Lu et al corroborated the infarct-
sparing effect of morphine in rats at 0.3 mg/kg intravenously.84  
Bilir et al. showed that tramadol, an agonist and antagonist of ORs, increases the 
isolated rat heart’s tolerance to I/R.85 In a clinical trial tramadol was given prior to coronary 
artery bypass surgery.86 Surprisingly, tramadol caused an increase in a marker of 
cardiomyocyte necrosis, cardiac troponin I (cTnI) in the blood of patients suggesting that this 
opioid actually exacerbates injury of the heart during coronary artery bypass surgery. This 
demonstrates why results of any animal study must be tested in clinical trials.   
Irwine’s group was the first to demonstrate remifentanil induced cardioprotection in 
both in vivo and isolated heart models.87,88 The infarct-reducing effect of remifentanil was 
abolished by pretreatment with the selective κ OR antagonist nor-binaltorphimine and the 
selective δ OR antagonist naltrindole. Later the cardioprotective effect of remifentanil was 
confirmed in an isolated perfused rat heart.89 In 2010, a clinical trial of remifentanil was 
carried out.90 Forty patients with on-pump coronary artery bypass surgery were included in 
this trial. All patients were anesthetized with propofol and pretreated with fentanyl. Some of 
the patients (n = 20) received remifentanil (1 μg/kg intravenously and then infusion with rate 
of 0.5 μg/kg during 30 min) prior to surgery. Cardioprotection was determined 24 hr 
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postoperatively by assessing biochemical markers of myocardial necrosis: creatine kinase MB 
(CK-MB) and cTnI.  CK-MB and cTnI levels were significantly lower in patients that 
received remifentanil.90 Thus, unlike tramadol, remifentanil appears to be cardioprotective not 
only in animals but also in patients with I/R injury of heart. 
Pretreatment with the selective δ1 OR agonist TAN-67 (10 mg/kg intravenously) 
decreased the IS/AAR in rats and the selective δ1 OR antagonist BNTX abolished the effect.91  
This experiment indicated that the δ1 OR was protective and a year later, using an isolated 
perfused heart, it was shown that the δ OR-selective agonist DADLE could also protect.92 
More recent studies indicate that 10 mg/kg DADLE prior to coronary artery occlusion 
decreases IS/AAR and the highly selective δ OR antagonist naltrindole abolished this effect.93 
The cardioprotective effect of DADLE was confirmed in later investigations.94, 95 In vivo, this 
peptide exhibited an infarct-reducing effect in rats at a dose of 1 mg/kg.94 It was also found 
that the μ OR-selective agonist methadone (0.3 mg/kg) shows an infarct-reducing effect, 
which is actually mediated via δ OR activation.96 
Takasaki et al. found that cardiomyocytes tolerance to hypoxia/reoxygenation is 
increased after addition the μ and δ OR agonist met-enkephalin to the incubation buffer.97 
Later, this team of investigators using naltrindole showed that the cytoprotective effect of 
met-enkephalin is mediated via δ OR occupancy.98 Infusion of met-enkephalin to rabbits 
starting 24 hr before coronary artery occlusion with an osmotic minipump promoted a 
decrease in the IS/AAR by 60%.99 However, a 24-hr infusion of met-enkephalin in mice 
failed to reduce the infarct size.100 This indicates again that there are species differences in the 
response to some opioids. This is most likely due to small but important differences in the 
genetic codes for these receptors among the species. In in vivo experiments with pigs, 
researchers could not demonstrate an infarct-reducing effect of DADLE at a dose of 1 mg/kg 
intravenously.101  
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The ability of the δ1 OR agonist TAN-67 to mimic the cardioprotective effect of 
preconditioning in rat heart was confirmed in the later studies both in vivo102 and in vitro103-
105. We established that perfusion of the isolated rat heart with the δ1 OR-selective agonist 
DPDPE (154 nM) decreases reperfusion-induced creatine kinase release.106 Pretreatment with 
the δ OR-selective antagonist naltrindole (1 nM) completely abolished DPDPE’s 
cardioprotective effect. In 2001, McPherson and Yao107 showed that the δ-selective agonist 
BW373U86 (10 pM) increases tolerance of isolated cardiomyocytes to 
hypoxia/reoxygenation. The cardioprotective property of TAN-67 and BW373U86 were 
confirmed in vivo at coronary artery occlusion and reperfusion.108,109 In addition, it was 
established that the infarct-sparing effect of BW373U86 (1 mg/kg) is a consequence of δ1 OR 
activation109.  
In pigs, an infarct-reducing effect of DPDPE was found at a dose of 1 mg/kg 
intravenously101 but this dose was not protective in rats.110,111 Again, a species difference was 
present. DPDPE at the final concentration of 0.1 mg/L (154 nM) did protect the isolated 
perfused rat heart112,113 and DPDPE’s protection in rat heart can be blocked by 
naltrindole.104,106,114 The infarct-sparing effect of DPDPE was confirmed in experiments in the 
isolated rat heart by M.H. Huang et al.52 In 2006, Watson et al. reported that the δ1 and δ2 OR 
agonist ARD-353 (0.3 mg/kg) decreased the IS/AAR in rats.115 This effect disappeared after 
δ1 OR inhibition with BNTX. In addition, Watson et al. obtained data that ARD-353 does not 
penetrate through the BBB.115 These authors concluded that the cardioprotective effect of 
ARD-353 is a consequence of peripheral δ1 OR activation. In 2006, E.R. Gross et al.116 
reported that the δ OR agonist fentanyl isothiocynate caused infarct reduction at a dose of 10 
μg/kg intravenously. Hence, there is a reason to believe that the δ1 OR agonists are excellent 
candidates for cardioprotective drug development. 
B. δ2 opioid agonists 
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 In 2002, in experiments with pigs, we demonstrated the infarct-reducing effect of the 
putative δ2 OR agonist deltorphin D at a dose of 1 mg/kg.101 In 2009, in experiments with rats, 
we confirmed these data.117 The selective δ2 OR agonist deltorphin II at a dose of 0.12 mg/kg 
can decrease the IS/AAR. The infarct-sparing effect of deltorphin II was maintained in the 
presence of the δ1 OR antagonist BNTX but disappeared after δ2 OR block with naltriben.117 
The cardioprotective effect of deltorphin II was abolished after blocking peripheral OR with 
naloxone methiodide (5 mg/kg). Hence, the δ2 OR also seemed to be protective.  
C. κ opioid agonists 
The κ1 OR-selective agonist U50,488 increases the tolerance of isolated 
cardiomyocytes to sodium cyanide toxicity in the incubation buffer.118 They showed that 
U50,488 (10 μM) decreases the IS/AAR in the isolated perfused rat heart. We confirmed that 
pretreatment with U50,488 protects the isolated perfused rat heart to global I/R.113,119,120 
Addition of κ OR-selective agonist dynorphin to incubation buffer increases tolerance of 
rabbit cardiomyocytes to 3 h of hypoxia  and the κ OR-selective antagonist GNTI abolished 
dynorphin’s protection.98 In 2004, it was shown that pretreatment with the κ OR agonists 
U50,488, ICI 204,448 and BRL 52537 exhibit infarct-reducing effect in vivo.121 The κ OR-
selective antagonist nor-binaltorphimine abolished the infarct-sparing effect of U50,488 and 
ICI 204,448 but did not affect the cardioprotective effect of BRL 52537.121 Since ICI 204,448 
does not penetrate through the BBB,122 it is likely that the peripheral κ OR activation 
promotes the protection. The anti-necrotic effect of U50,488 is seen in the isolated heart. 
Recently, we have found that the quaternary ammonium salt of U50,488 (Q-U50,488) which 
is not able to pass the BBB, elicits a protective effect against cardiac I/R injury.123 The 
infarct-sparing effect of Q-U50,488 was abolished by nor-binaltorphimine implicating a 
peripheral κ OR. It can safely be assumed that the κ OR regulating cardiac tolerance to 
ischemia/reperfusion is located in the heart. 
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D. μ opioid agonists 
Using isolated perfused rat heart we found that the μ OR-selective agonist DAMGO 
reduces infarction after global I/R.124 The protection from DAMGO was confirmed in our 
later investigations.125,126 In addition, we established that the μ OR-selective agonist DALDA 
also can prevent cardiac cell death during global I/R. However, intravenous DAMGO (0.1 
mg/kg) or DALDA (0.1 mg/kg) 15 min prior to heart isolation actually increased the injury 
from I/R ex vivo.125-127 Gross’s group found that DAMGO (0.1 mg/kg intravenously) had no 
effect on the IS/AAR in rats after I/R in vivo.128 In our in vivo investigation in rats with 
coronary artery occlusion (45 min) and reperfusion (2 h), we studied the μ OR-selective 
agonist dermorphin H (0.12 mg/kg) and DAMGO (0.08 or 0.8 mg/kg).110,111 Neither of these 
peptides had any effect on the IS/AAR. It remains unclear why DAMGO is so protective ex 
vivo but not in vivo.  
Gross et al. found that the μ and δ OR-selective agonist Eribis peptide 94 starting 10 
min after coronary artery occlusion (30 min) and continuing during reperfusion decreases the 
IS/AAR in open-chest rats. This protection persisted after inhibition of δ OR with naltrindole, 
δ1 OR with BNTX and κ OR with nor-binaltorphimine. However, it was abolished with the 
selective μ OR antagonist CTOP.129 This was the first convincing evidence that μ OR 
activation protects the heart from ischemia/reperfusion.  
E. ORL1 opioid agonists 
Recently, we evaluated a fourth OR subtype which usually denoted as ORL1 receptor 
(opioid-like receptor 1) in an in vivo rat model using the endogenous ORL1-selective agonist 
Nociceptin Neither 0.4 or 2.2 mg/kg had any effect on the IS/AAR. 110,111 In our opinion, it is 
too early to draw a final conclusion that ORL1 receptors do not affect the heart’s tolerance to 
I/R because we have not yet studied it in the isolated heart. The μ OR agonists are 
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cardioprotective ex vivo but not in vivo and it is possible that nociceptin may act in a similar 
fashion. 
 
4. Toxicity of High Dose Opioids and the Cardioprotective effects of OR 
Antagonists 
The aforementioned studies demonstrate that OR activation can increase the heart’s 
tolerance to ischemia/reperfusion but there are some studies demonstrating that OR 
stimulation can also exacerbate I/R injury. Intravenous administration of morphine at a dose 
of 2.1 mg/kg can induce ST segment depression in patients with ischemic heart disease.130 
The authors interpreted this effect as a manifestation of myocardial ischemia. In another 
study, it was shown that morphine at a dose of 1 mg/kg increases ST segment elevation in cats 
with coronary artery ligation, which they regarded as worsening of the heart’s ischemia.131 In 
1982, the same group of authors did obtain data that morphine can increase the infarct size in 
rats.132 Morphine was administered at a dose of 3 mg/kg intravenously for 10 min prior to a 
48-h coronary artery occlusion without reperfusion. Permanent occlusion without reperfusion 
in rodent hearts is now considered as an invalid methodology for evaluating cardioprotection 
since cardiac muscle cannot survive in the complete absence of blood flow. In addition, these 
data contradict the results of the Chinese investigators, which showed that morphine at a dose 
of 8 mg/kg evokes a decrease in the IS/AAR.83 We tested 0.3, 0.8. and 3.0 mg/kg morphine 
pretreatment in open-chest rabbits and found no effect of the two lower doses but greatly 
reduced infarct size with the high dose.81 
In 1985, it was reported that 1.1 or 3.6 mM naloxone in the perfusion solution protects 
the isolated heart.133 Naloxone’s IC50 towards μ and δ OR is 8.2 nmol.134 Similarly, the Ki of 
naloxone towards μ OR is reported to be 3.4 nmol but that towards δ OR is 50 nmol.135 We 
would suggest that the cardioprotective effect of their very high-dose naloxone is probably a 
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non-specific membrane stabilizing effect of the drug, rather than a consequence of the 
blockade of ORs. It should also be noted that in most of our experiments we have not 
observed infarct-reducing effect of naloxone, naltrexone and most of other OR 
antagonists.81,110 Similarly, many other investigators failed to observe a cardioprotective 
effect of the OR antagonists in situ or in vitro. An exception is the work of Chen et al. They 
performed 45 min global ischemia and 60 min reperfusion of an isolated rat heart in which 
OR antagonists were added to perfusion buffer for the first 10 min of reperfusion. Necrosis 
was evaluated by IS/AAR and by monitoring CK-MB levels in coronary effluent.  Naloxone 
(10 nM), naltrindole (5 nM), or nor-binaltorphimine (5 nM) decreased the IS/AAR and CK-
MB release.136 Hence, these OR antagonists mimic IPost phenomenon. The concentrations of 
antagonists indicators used approach their published Ki and IC50.
134,135,137 Therefore, we 
cannot easily dismiss the cardioprotective effect of OR antagonists as a nonspecific effect. We  
found that intravenous administration of the μ OR antagonist CTAP (1 mg/kg) to rats prior to 
coronary artery occlusion (20 min) and reperfusion (3 h) promotes a decrease in the 
IS/AAR.138 However, protection may have been mediated via the somatostatin receptor for 
which this peptide exhibits moderate affinity.139  Somatostatin is known to limit the IS/AAR 
in in vivo studies.140  
Our investigations do indicate the existence of an OR pool, or non-ORs, whose 
activation with opioids negatively affects cardiac tolerance to I/R.104,112 In isolated rat heart 
studies, we observed that the cardioprotective effect of the δ1 agonist DPDPE disappears if the 
concentration of peptide in the perfusion buffer is increased to 740 nM. 104,112 In isolated 
murine heart, 10 μM of morphine was not protective141 while 0.3 μM did protect isolated 
rabbit heart.81 It seems highly likely that concentration of 10 μM was so high that morphine 
began binding to a pool of receptors that negatively affected the heart’s tolerance to I/R. 
Gross’s group was unable to protect hearts with 1 μM BW373U86 in isolated murine hearts141 
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while BW373U86 did protect isolated chick cardiomyocytes but only at a concentration of 10 
pM.107 Mixing species always complicates interpretation but an obvious explanation is that 
overdosing can lead to negative off target effects. We recommend that ex vivo and in vitro 
experiments should test agonists at a concentration 10-fold higher than the Ki or EC50.
81 They 
should also be aware that the binding affinities of these drugs can vary widely among species.   
Aitchison et al. reported that DADLE at 10 nM exhibits infarct sparing that was 
diminished at 1 μM. Inhibition of κ OR with nor-binaltorphimine restored the full 
cardioprotective effect of high concentration DADLE.142 The authors concluded that the 
diminished effect of DADLE at high concentration is due to activate κ OR. These data closely 
resemble our results with DPDPE. 104,112 In addition, Aitchison et al. established that the non-
selective κ OR agonist bremazocine (30 nM) ex vivo increased infarct size.142 This negative 
effect of bremazocine disappeared after inhibition of κ OR. In this regard it should be noted 
that U50,488 is the selective κ1 OR agonist but bremazocine is an agonist of κ2 OR.143 It 
seems reasonable to assume that the activation of κ2 OR exacerbates injury from I/R. 
In 2005, Meine et al. published the results of a prospective, nonrandomized study, 
which included patients with acute coronary syndrome (ACS) with non-ST-segment elevation 
(NSTE) (n = 57,039).144 The authors evaluated the outcome of patients treated with morphine 
and those who were not. It was found that treatment with morphine was associated with 
increased risk of in-hospital mortality. The authors raised concerns about the safety of using 
morphine in patients with ACS NSTE but pointed out that that could only be answered with a 
randomized trial.144 These data were in accord with a few other studies.130,145-146 In particular, 
Conahan et al. demonstrated that morphine (2 mg/kg) caused severe hypertension and an 
increase in systemic vascular resistance in patients undergoing heart valve replacement.146 
Later Lappas et al. reported that the addition of 5% NO to morphine (2 mg/kg intravenously) 
decreased blood pressure, cardiac index, stroke index and increased pulmonary capillary 
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wedge pressure.146 Intravenous administration of morphine at a dose of 2.1 mg/kg can induce 
ST segment depression in patients with ischemic heart disease.130 However, we would like to 
draw readers’ attention to the fact that an extremely large dose of morphine (2 mg/kg) was 
used in these 3 studies.130,145-146 Indeed, in current cardiological guidelines, the recommended 
dose of morphine is 4 - 8 mg (0.05 - 0.1 mg/kg).147 Experimental studies suggest that 
morphine has the infarct-limiting effect at a dose of 0.3 mg/kg.10 It comes as no surprise that 
morphine can provide an adverse effect on the cardiovascular system at a dose many times 
exceeding the therapeutic dose. In cardiological practice, morphine and fentanyl are used not 
only for pain relief in patients with AMI but also to ease anxiety, reduce preload, due to 
venodilation,147-149  and afterload, due to reducing systemic vascular resistance.148,150 It has 
been established that morphine and fentanyl can decrease myocardial oxygen consumption 
and reduce lactate production by the left ventricle in human.151 Both of those effects may 
increase cardiac resistance to ischemia and improve the outcome in AMI. Morphine is also 
used for the prevention of pulmonary edema, and cardiogenic shock.152 Therefore, morphine 
and other opioids are prescribed in the most serious cases characterized by a higher mortality 
than in patients with mild AMI, like those included in the study of Meine et al.144 An 
overdose of opioids may cause a depression of respiration, hypotension and vomiting.152 
In summary, pretreatment with agonists of μ, δ1, δ2 and κ1 OR exhibit cardioprotective 
properties  both in vivo and in vitro. These pharmacological agents mimic the preconditioning 
phenomenon. The role of the ORL1-receptors in this regard remains open, however. A 
number of reports points to the existence of important species differences in the reaction of 
infarcted myocardium to opioids. Some receptors, such as κ2 ORs, may actually exacerbate 
the ischemic and reperfusion heart injury. But the agonists of , δ1, δ2 and κ1 ORs can be 
considered as the most promising group of agents able to induce cardioprotection. This 
opinion can be supported by numerous studies.80,87,93,96,98,106,109,110,115,116,121,128,129 
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5. Anti-apoptotic Effect of the Opioid Receptor Agonists  
It is well known that reperfusion induces enhancement of production of reactive 
oxygen species (ROS)153 and Ca2+ overload in cardiomyocytes.154 Calcium ions and ROS 
evoke opening of MPT (mitochondria permeability transition pore) which is a protein 
supramolecular complex built into the outer and inner mitochondrial membrane.155,156 
Opening of this pore collapses the potential across the inner mitochondrial membrane, which 
prevents ATP generation by the mitochondria.  MPT also releases cytochrome c and AIF 
(apoptosis inducing factor) in the intermembrane space into the cytosol.155,156 Cytochrome C 
together with APAF-1 (apoptosis protease activating factor), procaspase-9 and ATP form a 
supramolecular complex named apoptosome.156 The apoptosome catalyzes proteolysis of 
procaspase-9 to become active caspase-9, which in turn catalyze the cleavage of other 
proteins ultimately leading to apoptosis, a process in which the cell is killed and digested from 
within over several days. Protein AIF activates translocation of endonuclease G from cytosol 
into nucleus where the latter catalyzes DNA fragmentation that is a characteristic of apoptotic 
cells.156 These events are developed mainly during the first minutes of reperfusion. Therefore, 
the opening of MPT is a major cause of death of cardiomyocytes after the restoration of 
coronary blood flow.155  Necrosis quickly ensues if too many mitochondria within the cell are 
lost to MPT and the cell becomes tetrazolium negative (popular marker for infarct size 
studies) minutes after reperfusion due to membrane failure. If only a small fraction of the 
mitochondria are involved, however, the cell may survive the initial I/R only to succumb to 
apoptosis a day or two later. Apoptotic cells are tetrazolium positive in the first hours of 
reperfusion. The evidence is strong that IP protects by inhibiting MPT formation at 
reperfusion.157 Generally, apoptosis and necrosis act in parallel and markers of apoptosis can 
be used to assess injury from I/R.  
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The first work indicating that opioids inhibit apoptosis of cardiomyocytes was 
published in 2001. Isolated chicken embryo cardiomyocytes were subjected to 12-h of 
hypoxia and 12-h of reoxygenation. Apoptosis was evaluated by the number of TUNEL-
positive cells (terminal deoxyribonucleotide transferase-mediated dUTP nick end labeling). 
Fifty four % of the cells were TUNEL-positive. However, if BW373U86 (20 pM) was added 
to medium only 39 % of the cells became apoptotic. The selective inhibition of δ1 OR with 
BNTX abolished the cytoprotective effect of BW373U86.158 Okubo et al. found that opioids 
can exert an anti-apoptotic effect in vivo. Morphine at 0.3 mg/kg prior to coronary artery 
occlusion reduced the number of TUNEL-positive cells in the heart from 12.4% in control to 
only 5.2%. The δ OR antagonist naltrindole (10 mg/kg intravenously) abolished the effect of 
morphine.159 These findings led the investigators to conclude that the anti-apoptotic effect of 
morphine was dependent upon δ OR activation. The anti-apoptotic effect of morphine on 
isolated cardiomyocytes was confirmed in later experiments.160 In isolated perfused rat hearts 
exposed to 30 min global ischemia and 60 min reperfusion 16% of the cells were TUNEL-
positive but with 3 μM morphine in the perfusion solution decreased this index to 5%.161 In 
2012, Kim et al. using isolated cardiomyocytes found that addition of remifentanil to the cell 
incubation medium  prior to hypoxia/reoxygenation increased cell survival , decreased the 
concentration of Ca2+ in the cytoplasm, decreased activity of caspase-3, increased anti-
apoptotic protein Bcl-2 (B-cell lymphoma protein-2) over that in untreated cells.162 In 2009, it 
was noted that the selective κ1 OR agonist U50,488 causes an anti-apoptotic effect.163 This 
study was performed in rats with coronary artery occlusion (45 min) and reperfusion (3 h). 
The κ1 OR agonist U50,488 was administered intravenously prior to ischemia. The number of 
TUNEL-positive cells in the area of I/R was 21.3% but in animals receiving U50,488 this 
number dropped to12%. The selective κ OR antagonist nor-binaltorphimine eliminated this 
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effect indicating that the anti-apoptotic effect of U50,488 was mediated via κ1 OR activation. 
We recently confirmed their hypothesis using Q-U50,488, which does not crosses the BBB.123 
The aforementioned studies suggest that δ and κ1 OR activation reduces the 
appearance of apoptosis of cardiomyocytes following reperfusion. It has not been determined 
whether agonists of μ OR and ORL1 receptors can prevent apoptosis of cardiomyocytes. 
 
6. Opioids Can Mimic Delayed Ischemic Preconditioning  
Fryer et al. found that 24 h after injection of TAN-67, there was a return of protection 
against I/R. Combining TAN-67 with the δ1 OR antagonist BNTX abolished this delayed 
protection. The authors concluded that the delayed protective effect of TAN-67 is depended 
upon δ1 OR activation.164 The delayed protective effect of TAN-67 was confirmed in later 
works.165,166 In 2004, it was found that the non-peptide δ OR-selective agonist SNC-121 
caused a delayed widow of protection in rats and surprisingly its protection was retained after 
inhibition of ORs with naloxone.167 The authors concluded that the cardioprotective effect of 
SNC-121 was not dependent on OR and illustrates the importance of testing with antagonists. 
Shinmura and colleagues found that the selective δ OR agonist BW-373U86 can mimic 
delayed preconditioning.168 Other investigators found that the non-peptide δ1 and δ2 OR 
agonist ARD-353 (0.3 mg/kg) evoked delayed conditioning.115 Morphine (3 mg/kg) also 
triggered delayed conditioning169 as did morphine at a dose of 0.3 mg/kg.170 OR antagonists 
were not used in these two studies. Hence, the responsible for delayed protective effect OR 
was not identified. 
A 30-min incubation of isolated cardiomyocytes with U50,488 for 20 h prior to 
hypoxia/reoxygenation increases cell tolerance to hypoxia/reoxygenation.171 This effect of 
U50,488 did not occur after κ OR inhibition with nor-binaltorphimine. The delayed 
preconditioning phenomenon of U50,488 was confirmed in later works by the same 
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authors.172,173 Intravenous administration of remifentanil, a non-selective OR agonist, can 
induce a delayed cardioprotective effect174 and this was confirmed by other investigators.175 
All three OR antagonists (CTOP, nor-binaltorphimine, naltrindole) abolished infarct-sparing 
effect remifentanil.174 Participation of ORs in the delayed cardioprotective effect of 
remifentanil has been confirmed by Sun et al.175  
 
7. Involvement of endogenous opioids in the infarct-reducing effect of remote 
ischemic preconditioning 
In 2001, Dickson et al attempted to clarify the nature of the humoral factor(s) 
mediating the infarct-reducing effect of remote ischemic preconditioning (RIPC).176 
Preconditioning of isolated perfused rabbit hearts was reproduced by three 5-min episodes of 
ischemia interspersed with 10 min of reperfusion. Coronary effluent was collected, purified 
and concentrated using Sep-Pak C-18 columns. They demonstrated that concentrated 
coronary effluent introduced to other isolated rabbit hearts can protect these hearts against 
ischemia (40 min) and reperfusion (120 min). This protective effect was eliminated by 
pretreatment with naloxone.176 In the next study, isolated jejunal segments were subjected to 1 
h of simulated ischemia followed by 30 min of reoxygenation.177 Pretreatment with coronary 
effluent concentrate also improved contraction of the jejunal segments during reperfusion. 
Naloxone abolished the inotropic effect of the coronary effluent. Authors believe that 
coronary effluent contains opioids, which mediate a protective effect of RIPC.177 The authors 
hypothesized that the endogenous mediator of the cardioprotective action of RIPC is 
endogenous opioid peptide Met5-enkephalin-Arg6-Phe7.178 Patel et al. hypothesized that 
mesenteric preconditioning evokes release of endogenous opioids that protect the heart 
against I/R.179 Rats were subjected to coronary artery occlusion (30 min) followed by 
reperfusion (2 h). Experimental groups underwent occlusion of the mesenteric artery (15 min) 
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followed by reperfusion (10 min). Pretreatment with naloxone abolished the protective effects 
of RIPC.179 These data indicate that mesenteric preconditioning evokes release of endogenous 
opioid peptides that protect the myocardium against I/R. Weinbrenner et al. assumed that 
infarct-sparing effect mediated by infrarenal occlusion of the aorta (IOA) may be transmitted 
by endogenous opioids.180 They established that IAO induced protected against I/R and this 
was abolished by pretreatment with the selective δ1 OR antagonist BNTX (7-
benzylidenenaltrexone).180 These results indicate that the protection by RIPC is transmitted by 
δ1 OR occupancy. Another group induced RIPC in rats by three cycles of femoral artery 
occlusion (5 min) followed by reperfusion (5 min).181 They demonstrated that RIPC evokes 
increase in plasma dynorphin (a non-selective κ OR agonist), but not met-enkephalin (a μ OR 
and δ OR agonist) level. Pretreatment with the selective κ OR antagonist nor-binaltorphimine 
eliminated the infarct-sparing effect of RIPC. The selective δ OR antagonist naltrindole had 
no effect on the remote preconditioning.181 Hence, endogenous κ OR agonists, apparently 
dynorphin, mediate the cardioprotective effect of RIPC. Later, Rehmi et al. reported the 
participation of endogenous opioids in RIPC.182 Rentoukas et al. reported that morphine in 
combination with RIPC reduced infarct size in patients with primary percutaneous coronary 
intervention while RIPC alone did not.183  
Thus, today, there is no doubt that endogenous opioid peptides participate in the 
mechanism of the cardioprotective effect of RIPC. However, it remains unclear what kinds of 
ORs are involved in the RIPC phenomenon. The aforementioned Met5-enkephalin-Arg6-Phe7 
and dynorphin are unlikely mediators of RIPC since they are not resistant to enzymatic 
hydrolysis.184,185 
 
8. Opioids Mimic Postconditioning Phenomenon  
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The aforementioned studies demonstrate the ability of opioids to protect when applied 
as a pretreatment. A major indication for cardioprotection is acute coronary syndrome where 
the patient presents with ischemia already in progress. That makes pretreatment impossible so 
a postconditioning drug intervention is needed. Because much of the cell death in the heart is 
from MPT that form at reperfusion it is theoretically possible to protect against infarction 
right up to the time of reperfusion. IPost has been shown to limit infarct size.7 Is it possible 
that OR agonists at reperfusion might also protect? 
There are a few publications that indicate that the OR agonist can protect when 
administered at the end of the ischemic period.  In one such study, rats were exposed to 1 h 
coronary artery occlusion and 2 h reperfusion. When 0.3 mg/kg morphine was administered 
intravenously 10 min prior to reperfusion it evoked a decrease in the IS/AAR from 45% to 
30%.186 ARD-353 administered after 30 min of ischemia at a dose of 0.3 mg/kg immediately 
before removing the ligature decrease the IS/AAR from 55% to 35%.115 Since ARD-353 does 
not penetrate the BBB, these authors concluded that its infarct-reducing effect is mediated via 
peripheral OR.115  Tsutsumi et al. studied mice with 30 min coronary artery occlusion and 2 h 
reperfusion. The δ OR agonist SNC-121 (10 mg/kg) was administered intravenously 3 min 
before reperfusion. The control IS/AAR was 44% but only 24% in SNC-12-treated mice.187 
This study did not evaluate the role of OR antagonists.  
The OR agonists mimic IPost not only in vivo but also ex vivo. In one study, the 
isolated perfused rat heart was exposed to 45 min global ischemia and 60 min reperfusion.136 
Morphine was added to the perfusion buffer at 0.3, 3, and 30 μM for the first 10 min of 
reperfusion. Necrosis was assessed by tetrazolium staining and by CK-MB in coronary 
effluent. Morphine decreased the IS/AAR at 0.3 μM and more so at 30 μM. Pretreatment with 
naloxone or nor-binaltorphimine attenuated the protection.136 Unfortunately, the OR 
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antagonists (naloxone, naltrindole, and nor-binaltorphimine) exerted a small but significant 
cardioprotective effect by themselves which complicates the interpretation.  
In 2008, Jang et al. studied isolated rat heart with 30 min coronary artery branch 
occlusion and 2 h reperfusion. Either morphine (1 μM) or the δ OR agonist BW373U86 (1 
μM) were added to the perfusion solution starting 5 min prior to reperfusing the occluded 
coronary branch. The total duration of perfusion with agonists was 15 min. Both agonists 
decreased the IS/AAR by 3 fold.188 Pretreatment with naltrindole (100 μM) abolished the 
infarct-sparing effect of both agonists. Unfortunately, the authors used naltrindole in a 
concentration sufficient to inhibit all OR subtypes.135 Using isolated perfused rat heart, 
Mourouzis et al reported that 10 μM morphine can mimic IPost.189 The ability of morphine at 
1 μM to postcondition was also reported elsewhere.190,191  In vivo I/R experiments in rats 
showed that intravenous administration of U50,488 (0.1 mg/kg) 5 min prior to reperfusion 
promotes a decrease in the IS/AAR  but U50,488 10 sec prior to reperfusion had no effect on 
the IS/AAR.192 They also studied U50,488 (100 nM) in an isolated murine heart. The κ OR 
agonist was added to Krebs-Henseleit buffer at the beginning of reperfusion and it decreased 
the IS/AAR.192 They did not test OR antagonists. However, this does not invalidate their 
conclusion that U50,488 protected via κ1 OR because Ki of U50,488 for κ1 OR is 7.4 nmol but 
the Ki of U50,488 for μ OR is 256 nmol.134  
Methadone administered to an in situ rat experiencing 30-min ischemia at a dose of 
0.3 mg/kg for 5 min prior to reperfusion reduced infarct size. But if the injection was 
performed 10 sec after removal of the ligature, no changes in the IS/AAR could be detected.96 
If the duration of ischemia of the heart was 45 min, the injection of methadone 5 min before 
reperfusion also had no effect on the IS/AAR. The authors concluded that this opioid mimics 
IPost if it is administered 5 min before reperfusion.96 Remifentanil was infused intravenously 
for 5 min starting 5 min before reperfusion in rats with 30 min coronary artery occlusion and 
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2 h reperfusion. The IS/AAR was reduced by a dose of 10 μg/kg. Blocking δ or κ OR but not 
the μ OR by the agonist CTOP eliminated the protection.193 The ability of remifentanil to 
simulate IPost phenomenon was confirmed in another study performed in the isolated 
perfused rat heart.194 
In 2011, it was reported that 1 μg/kg of a tetrapeptide referred to by the authors as 
Eribis peptide 94 (EP94) decreased the IS/AAR in rats at reperfusion.195 These authors did not 
confirm a role of ORs in the infarct-reducing effect of EP94 but the authors did note that 
EP94 is a μ and δ OR agonist. Such a high potency of EP94 is surprising. However, in a later 
study by the same authors, it was reported that EP94 had an infarct-sparing effect at a dose of 
25 μg/kg but had no effect on the infarct size at the dose of 1 μg/kg.196 A 2012 study indicated 
that sufentanil simulates the IPost phenomenon at a dose of 1 μg/kg.197 It is known that 
sufentanil is also a selective agonist of μ OR.198 A further increase in the dose of this opioid 
did not lead to an enhancement of the infarct-reducing effect.197 These data were confirmed in 
a later paper by the same group.199 Unfortunately, these researchers did not test OR 
antagonists, therefore, it remains unclear whether the cardioprotective effect of sufentanil is 
depended upon μ OR activation. Most recently, in the experiments on isolated perfused rat 
heart, the non-selective OR agonist remifentanil at reperfusion was protective.200 The infarct-
reducing effect of this opioid was eliminated by naloxone but the investigators did not use any 
of the selective OR antagonists. 
 Thus, the aforementioned studies provide ample evidence that activation of δ and κ1 
OR can postcondition the heart. It remains unclear whether agonists of μ OR and ORL1 are 
also protective at the time of reperfusion.  
 
9. Localization of Opioid Receptors that Protect the Heart from 
Ischemia/Reperfusion  
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Studies on the isolated heart seem to indicate that the infarct-limiting effect of opioids 
is associated with the occupancy of the cardiac ORs. However, one should pay attention to 
two facts: (1) most studies have used OR ligands that penetrate the BBB; (2) in some studies 
the OR agonists were used in very large doses.81,91,187 For example, TAN-67 was used at a 
dose of 10 mg/kg.91 But according to Knapp et al. the Ki of TAN-67 for δ OR is 0.65 nmol.201 
For comparison, the Ki of morphine against δ OR is 49 nmol.135 One can assume that in order 
to limit the size of myocardial infarction, a larger dose of morphine would be required. 
However, it has been demonstrated that morphine is protective at a dose of only 0.3 mg/kg in 
rats.9 An interesting possible explanation of this paradox could be that TAN-67 activates a 
central δ OR that remotely increases cardiac tolerance to I/R via neural pathways and the low 
penetration of the BBB for TAN-67 requires a higher dose.  
There is a direct evidence of participation of central ORs in cardioprotection. A rat 
study with 30 min coronary artery occlusion and 90 min reperfusion showed that intrathecal 
administration of morphine (0.3 μg/kg) for 20 min prior to ischemia promotes a decrease in 
the IS/AAR.202 In a similar study in 2009, intrathecal pretreatment with morphine again 
protected rat hearts in a dose-dependent manner.203 Intrathecal administration of CTOP, 
naltrindole or nor-binaltorphimine abolished the infarct-sparing effect and the authors 
concluded that all three (μ, δ, and κ) ORs are involved in the cardioprotective effect of 
morphine.203  The infarct-reducing effect of morphine during intrathecal administration was 
confirmed in 2010.204 A cardioprotective effect of morphine was seen when it was infused for 
the 5 min prior to reperfusion and could be blocked by inhibition of μ, δ or κ OR.205  
In a study in rats with coronary artery occlusion/reperfusion, morphine was 
administered intravenously at a dose of 0.3 mg/kg.84 Naloxone methiodide, which does not 
cross the BBB, was administered prior to morphine injection intravenously or intrathecally at 
a dose of 20 mg/kg or 20 μg/kg.84,206 Regardless of the route of administration, naloxone 
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methiodide abolished the infarct-sparing effect of morphine. The authors concluded that 
morphine protected through both central and peripheral ORs.  
In 2012, it was shown that intrathecal administration of morphine to rats decreased in 
the IS/AAR by twofold and the autonomic ganglion blocker hexamethonium completely 
abolished the protection.207 They concluded that the cardioprotective effect of morphine was 
mediated via central OR stimulation and signaling through the autonomic nervous system. In 
2014, it was found that intrathecal administration of μ OR agonist fentanyl evokes a decrease 
in the IS/AAR.208 These data also indicate that the infarct-reducing effect of opioids following 
intravenous administration may not only be a consequence of activation of peripheral but also 
of central ORs. The infarct-limiting effect of opioid peptide EP94 occurred after blockade of 
peripheral OR with naloxone methiodide but disappeared after blocking peripheral and central 
ORs with naloxone.129 These authors concluded that the infarct-reducing effect of EP94 is 
mediated via central OR activation. This result was surprising because opioid peptides usually 
penetrate the BBB poorly. For example, the opioid peptide dalargin exerts central effect only 
at a dose of 500 μg/kg.209 But Gross et al. used EP94 at a dose of 1 μg/kg.129  
Thus, central OR stimulation clearly can increases cardiac tolerance to I/R. On the 
other hand, there is ample data with isolated hearts that cardiac OR can also protect the heart. 
It remains unclear, therefore, to what extent the infarct limiting effect of opioids during 
intravenous administration is mediated via central OR activation. 
 
10. Effect of Opioids on Recovery of Cardiac Contractility During Reperfusion  
The above studies primarily concentrated on myocardial necrosis as the endpoint. 
Cardiac injury also manifests itself as a reduction in post-reperfusion cardiac contractility.  
That reduction can be from loss of muscle to necrosis or it can be due to stunning, which is a 
transient loss of contractility following I/R. Preservation of mechanical function after I/R is 
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paramount in the setting of cardiac surgery. Therefore, some studies used cardiac contractility 
as their endpoint rather than infarction.  
A. μ OR 
We found that intravenous administration of the μ OR-selective agonists DALDA (0.1 
mg/kg) or DAMGO (1 mg/kg) for 15 min prior to heart isolation promotes better recovery of 
ventricular developed pressure (LVDP) after I/R in the isolated rat heart. The μ OR-selective 
antagonist CTAP (0.1 mg/kg) completely abolished DAMGO’s protective effect. In contrast, 
perfusion of the isolated rat heart with DAMGO (0.1 mg/L or 195 nM) for 10 min prior to 
ischemia did not improve recovery of function.127 Only activation of the μ OR in vivo 
preserves post-ischemic contractility ex vivo. It is known that Ki of DAMGO for μ OR is 1.23 
nmol110 or 27 nmol210. Therefore, we can’t explain an absence of inotropic effect of DAMGO 
ex vivo by a too low concentration of peptide. The protective effect of the μ OR agonist must 
be dependent upon μ OR activation somewhere outside the heart.47,64,211    
B. κ OR vs δ OR 
In a study on isolated rat heart, it was seen that perfusion with 200 μM DADLE prior 
to hypothermic cardiac arrest decreases the post-ischemic rise in end diastolic pressure (EDP) 
but not the decline in left ventricular developed pressure (LVDP).92 In 1999, P.E. Benedict et 
al. subjected the isolated rabbit heart to cardioplegic arrest (2 h of 34oC ischemia) followed by 
reperfusion. Perfusion of the isolated heart with morphine prior to ischemia promotes an 
increase in contractility during reperfusion.212,213 The selective μ OR agonist fentanyl198 did 
not have a similar effect. Consequently, it may be concluded that positive inotropic effect of 
morphine was depended upon δ or κ OR activation. The British physiologists Kato and Foex 
subjected the isolated perfused rat heart to 30 min global ischemia and 60 min reperfusion. 
The heart was perfused with the μ OR agonist fentanyl (740 nM). Fentanyl increased LVDP, 
the rate of contraction and the rate of relaxation of heart during reperfusion and pretreatment 
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with naloxone abolished fentanyl’s protective effect. These authors concluded that the 
inotropic effect of fentanyl was dependent upon δ OR activation.214 Kato and Foex gave 
fentanyl at a concentration sufficient to occupancy μ, δ and κ OR.214 Therefore, in our 
opinion, the presented data do not allow one to make a conclusion that the protective effect of 
fentanyl is mediated via δ OR stimulation. To further complicate the issue, the same authors 
published a paper in 2000, which reported that there was no improvement of contractility in 
the reperfusion period after 740 nM fentanyl.215 It is unclear, which study is correct.  
Exposing the isolated rat heart to the selective κ1 OR agonist U50,488 (1 μM) for 2 
min starting 10 min prior to global I/R promoted an increase in LVDP in the reperfusion 
period.216 The κ1 OR agonist had no effect on the EDP when given only during reperfusion. 
The inotropic effect of U50,488 was blocked by pretreatment with the selective κ OR 
antagonist nor-binaltorphimine (1 μM during 4 min). These authors concluded that the 
protective effect of U50,488 was dependent upon κ OR activation. Their work could be 
criticized because they did not use U50,488 and nor-binaltorphimine at receptor-selective 
doses. The Ki of  U50,488 for κ1 OR is 0.89 nmol217 and the Ki of nor-binaltorphimine for κ 
OR is 0.18 nmol.218 Nor-binaltorphimine at the final concentration of 100 nmol will also 
inhibit δ OR.219  In 2001, Genade et al. found that perfusion of the isolated heart with 10 nmol 
DADLE prior to ischemia improved mechanical function after reperfusion.220 Since DADLE 
at 10 nmol should only interact with δ OR221, it may be assumed that the inotropic effect of 
DADLE was dependent upon δ OR activation.  
We perfused isolated rabbit heart with 2 mM DADLE for 15 minutes before 
cardioplegic arrest and a 2-h global ischemia followed by reperfusion.222 DADLE promoted 
an increase in LVDP over those hearts which were subjected to only cardioplegia.222 DADLE 
at the concentration of 2 mM activates all ORs.221,223  Therefore, it is not clear what OR 
subtype was involved in the protective effect of DADLE. We continued this study with swine 
34 
 
Cardioprotective Properties of Opioid Receptor Agonists 
hearts. After pretreatment with DADLE (1 mg/kg intravenously), morphine (1 mg/kg 
intravenously), or saline, hearts were excised and kept for 75 minutes at 4⁰C, then reperfused 
them in a four-chamber isolated working heart apparatus.224 We found that pretreatment with 
either DADLE or morphine promoted an increase in cardiac output during reperfusion. Since 
neither DADLE nor morphine are the δ OR-selective agonists, it remains unclear what OR 
subtype was involved. We suspect that the protective effect of DADLE was dependent upon μ 
OR stimulation as noted in another of our studies.127 Similar data were obtained by Shinmura 
et al. They injected the δ OR-selective agonist BW-373U86 (1 mg/kg) into rats 
subcutaneously either for 1 h or 24 h before the heart isolation. Isolated perfused rat hearts 
were subjected to 20 min of global ischemia followed by 20 min of reperfusion. Pretreatment 
with BW-373U86 improved LVDP during reperfusion.225 Such evidence indicated that BW-
373U86 mimics both preconditioning and delayed preconditioning. It was not determined as 
to what OR subtype(s) were involved.  
In 2002, Wu et al. subjected isolated perfused rat hearts to 30 min global ischemia and 
2 h reperfusion. Hearts were perfused with 100 nM [Dmt1]DALDA or 1 μM morphine  for 30 
min and then subjected to 30-min global ischemia. Reperfusion was performed using the same 
solutions. Both opioids increased contractile force during reperfusion over that seen with 
buffer only. The protection was present even when hearts were only perfused with 
[Dmt1]DALDA during reperfusion, whereas reperfusion with morphine only during 
reperfusion had no effect on the contractility.226 It is known that the peptide [Dmt1]DALDA is 
an agonist of μ and κ OR.227 Therefore, it remains open as to what OR was involved.  
Peart and Gross presented evidence that either δ or κ OR stimulation improves cardiac 
function during reperfusion.141 Isolated murine heart was subjected to 20 min global ischemia 
followed by 45 min reperfusion. The OR agonists were infused for 10 min prior to ischemia, 
and then throughout reperfusion. Infusion of 10 μM morphine induced an improvement in 
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post-ischemic recovery. Infusion with the selective δ OR agonist BW373U86 (1 μM) also 
improved recovery of LVDP. Pretreatment with the selective δ1 OR antagonist BNTX (1 μM) 
completely abolished this effect of BW373U86. Infusion of the selective κ1 OR agonist 
U50,488 (1 μM) produced a marked improvement in contractile recovery.141 This effect was 
blocked by the selective κ OR antagonist nor-binaltorphimine (1 μM).  
Gross’s group showed that pretreatment with the selective δ OR agonist DPDPE (1 
μM) also improves mechanical recovery of murine hearts following ischemia.228 In another 
study, cardioplegic arrest during global ischemia (2 h at 34oC) was induced and followed by 
reperfusion. Hearts which were pretreated with either the preferential δ OR agonist DADLE 
or the κ agonist OR U50,488 demonstrated significantly improved functional recovery versus 
controls. The selective μ OR agonist fentanyl had no effect on recovery.229 Selective 
antagonists were not tested. An improvement of contractility during reperfusion after U50,488 
was confirmed in isolated rat hearts.230 This effect was abolished after pretreatment with nor-
binaltorphimine indicating the protective effect of U50,488 is mediated via κ OR occupancy. 
Perfusion of the isolated rat heart with a solution containing the nonselective κ OR agonist 
pentazocine before or after 15 min global ischemia improved cardiac contractility during 
reperfusion.231 These authors did not test with the OR antagonists. It was also shown that 
preliminary perfusion of the isolated heart with 1 μM morphine for 15 min before global 
ischemia promoted an increase in LVDP in the reperfusion period.161 These authors also did 
not test any OR antagonist. It should be noted that some investigators did not find a positive 
effect of morphine or U50,488 on cardiac contractility although they did decrease infarct 
size.194,232  
 
11. Worsening of post-ischemic mechanical recovery by opioid ligands 
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In the above studies, we presented data that the OR agonist can prevent an appearance 
of reperfusion contractile dysfunction. However, there are reports that some opioids can also 
exacerbate contractile dysfunction. The κ OR agonist bremazocine exacerbates reperfusion 
contractile dysfunction of the isolated heart.142 It is known that bremazocine is a potent κ2 OR 
agonist.143 Therefore, the above presented data on the effects of the κ1 OR agonist U50,488 
and bremazocine do not contradict each other.  
We observed that intravenous administration of the δ1 OR-selective agonist DPDPE 
(0.1 or 0.5 mg/kg) 15 min prior to the heart isolation exacerbates reperfusion contractile 
dysfunction.112 If we added 0.1 or 0.5 mg/L DPDPE (154 nM or 771 nM) 15 min before 
global ischemia (45 min) and reperfusion (30 min), we also observed exacerbation of 
contractile dysfunction. DPDPE peptide can interact with only δ1 OR at the final 
concentration of 154 nM.198 Pretreatment with the selective δ OR antagonist naltrindole (1 
nM) completely abolished the negative inotropic effect of DPDPE (154 nM).106 We later 
found that the selective δ1 OR agonist TAN-67 (178 nM) also exacerbates dysfunction during 
reperfusion.103 Pretreatment with the selective δ OR antagonist naltrindole (1 nM) abolished 
this effect of TAN-67. Our above result is drastically different from the data of Gross’s 
group141,228 where they generally found protection from δ1 OR agonists. It worth mentioning 
that their schedule of drug administration was quite different from that used in the above 
studies, however. 
In most of the above studies, the ischemic period was long enough to cause some 
necrosis of the heart.  In those studies, the post-ischemic recovery is influenced by a 
combination of stunning and infarction; so it is not clear which was contributing to an 
enhanced post-ischemic improvement in mechanical function. This is important in that the 
mechanisms of the two forms of injury differ drastically. In 2006, Grosse Hartlage et al. 
employed a pure stunning model where a coronary branch of a chronically instrumented dog 
37 
 
Cardioprotective Properties of Opioid Receptor Agonists 
is given a 10 min coronary occlusion, which is too short to cause any infarction but does 
depress post-ischemic function. Function completely recovers spontaneously in a day proving 
that the segment was only stunned. They gave the selective κ OR receptor antagonist nor-
binaltorphimine (2.5 mg/kg intravenously). Pretreatment with the κ OR blocker prevented the 
decrease in ventricular wall function after ischemia. They found evidence that the endogenous 
opioid dynorphin was elevated in the plasma after the ischemic insult and concluded that this 
opioid was exacerbating the dysfunction in the untreated dogs.233 This data contradicts the 
abovementioned data on positive inotropic effect of the κ OR agonist U50,488 during 
reperfusion141,230 but those studies used isolated hearts with long ischemic periods where the 
agonist was confined to the pretreatment period. We found that perfusion of the isolated rat 
heart with solution containing U50,488 (0.1 μM) starting 10 min before global ischemia (45 
min) decreases creatine kinase release during reperfusion but depresses the recovery of 
contractile dysfunction.120 If we used U50,488 at the final concentration of 1 μM, the 
cardioprotective effect disappeared but the negative inotropic effect was enhanced.  
Thus, results of studies of the inotropic effects of opioids on cardiac stunning are very 
contradictory. Some studies indicated that pretreatment with opioids improves cardiac 
contractility in reperfusion period.92,127,161,213,214,216,220,222,225,226,230,231 Other studies showed 
that pretreatment with opioids exacerbate contractile dysfunction.103,106,112,120,142 Other 
investigators could not find any alteration of postischemic recovery after pretreatment with 
the OR agonists. 127,194,214,232 Much of this confusion no doubt arises from heterogeneity in the 
models (isolated vs. in situ), the schedule of drug administration (pretreatment vs. post 
treatment vs. continuous treatment), and the type of injury (infarction vs. stunning). 
Therefore, the resolution of possible inotropic effects of opioids during myocardial 
reperfusion remains to be determined.  
12. Antiarrhythmic Effect of the Opioid Receptor Ligands  
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The most frequent causes of death from myocardial infarction are cardiogenic shock 
(52%), arrhythmias (25%), thromboembolism of the pulmonary artery (10%), and rupture of 
the left ventricle (5%).234 These findings indicate that an antiarrhythmic drug could 
dramatically reduce mortality in this population. Opioids are potential candidates for 
developing such drugs. 
The first report that an OR agonist has an antiarrhythmic effect was with meptazinol 
during coronary artery occlusion in rats in 1983.235 In 1989, it was shown that the selective μ 
OR agonist fentanyl (60 μg/kg intravenously) increased the ventricular fibrillation threshold 
(VFT) in dogs with coronary artery occlusion.236 The μ and κ OR agonist buprenorphine had 
the same effect.236 The antifibrillatory activity of the μ OR agonists fentanyl, sufentanil and 
carfentanil in dogs with coronary artery occlusion was demonstrated by Hess et al. in 1989.237  
Clinical observations established that fentanyl (60 μg/kg intravenously) could prevent the 
appearance of intraoperative ventricular fibrillation during cardiosurgery intervention in 
neonates.238 These studies indicate that opiates can increase cardiac tolerance to the 
arrhythmogenic effect of ischemia/reperfusion.  
Unfortunately, these historical studies were performed before highly selective OR 
antagonists were widely available; so none of these publications contained this approach 
aimed to confirm a receptor-mediated effect and identify which subtype was responsible. 
Morphine is a μ OR-selective agonist as is fentanyl.198 However, it was later shown that the 
cardioprotective effects of morphine10 and fentanyl214 are actually dependent upon  OR 
stimulation. Furthermore, both narcotic analgesics easily penetrate through the BBB. 
Therefore, it was unclear whether their antiarrhythmic effect was dependent upon the central 
or peripheral OR occupancy. 
A. μ OR agonists 
In order to find out whether the peripheral ORs are involved in the arrhythmogenesis, 
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we used D-Ala2,Leu5,Arg6-enkephalin (dalargin). This compound can penetrate the BBB at a 
dose of 0.5 mg/kg and higher.209 We found that intravenous administration of dalargin (0.1 
mg/kg) decreases the incidence of ventricular fibrillation during coronary artery occlusion in 
rats.239 Other investigators confirmed our data in experiments on cats.240 According to the 
data of Grekova et al. dalargin (0.1 mg/kg) exhibits an antiarrhythmic effect when 
administered intravenously to dogs 5 min prior to coronary artery occlusion.241 Dalargin can 
prevent both ischemic and reperfusion arrhythmias. However, this opioid peptide was 
ineffective if it was administered after coronary artery ligation.241 Dalargin not only prevented 
the appearance of arrhythmias during ischemia, it also evoked an increase in the VFT in rats 
with postinfarction fibrosis.242 We therefore reasoned that the antiarrhythmic effect of 
dalargin is mediated via peripheral OR activation. However, it is still unknown what OR 
subtypes are involved in antiarrhythmic effect of dalargin because this peptide is a  and  
OR agonist.243,244 
We found that the injection of the selective μ OR agonist DALDA prior to a 10-min 
coronary artery occlusion and reperfusion in rats does not affect the incidence of ventricular 
arrhythmias.138 Nor could we find an antiarrhythmic effect of the selective μ OR agonist 
DMGO (150 or 1500 nmol/kg) or the μ OR agonist dermorphin H (150 nmol/kg) during 
coronary artery occlusion.245 In experiments with postinfarction cardiac fibrosis we obtained 
data that the nonselective  OR agonists morphine and dalargin and the  OR agonist 
DALDA increase the threshold for fibrillation.242,246,247 The antifibrillatory effect of DALDA 
(0.1 mg/kg) was not present after inhibition of the peripheral ORs with naloxone 
methiodide.247 We theorize that the antifibrillatory effect of DALDA is depended upon 
peripheral OR occupancy. Blockade with The  OR-selective antagonist CTAP (0.5 mg/kg) 
also abolished the antifibrillatory effect of DALDA.247 Therefore, it can be argued that 
DALDA induces an increase in cardiac electrical stability via the peripheral  OR activation. 
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Thus, peripheral  OR activation increases cardiac electrical stability in animals with 
postinfarction cardiac fibrosis but, based on our data, μ OR agonists do not suppress acute I/R 
arrhythmias.  
B.  OR and arrhythmias from acute ischemia/reperfusion 
In more recent experiments with the selective 1 OR agonists TAN-67 (0.08 mg/kg), 
DPDPE (0.1, 0.2 and 0.5 mg/kg) and the selective peptide agonist DSLET (0.11 mg/kg), we 
found that these ligands after intravenous administration had no effect on the incidence of 
ventricular arrhythmias during a 10-min coronary artery occlusion and reperfusion in rats.138 
However, we found that selective 2 OR activation with intravenous administration of 
deltorphin II (0.12 mg/kg or 150 nmol/kg) did reduce arrhythmias from I/R.138 We suspect 
that the strong antiarrhythmic effect of deltorphin II and the absence thereof, in DSLET is a 
consequence of different affinities of these ligands to  OR. Deltorphin II exceeds DSLET in 
two-fold in its affinity for  OR.248 Therefore, it is not surprising that when using both 
peptides in equimolar doses only deltorphin II was antiarrhythmic. Recently, we have shown 
the selective 2 OR agonist deltorphin II (150 nmol/kg) and the putative 2-selective 
deltorphin Dvar (150 nmol/kg) and deltorphin E (150 nmol/kg) had antiarrhythmic properties 
during coronary artery occlusion/reperfusion.245 We performed further studies on Deltorphin 
II, which exerted the most pronounced antiarrhythmic effect. Pretreatment with the 
nonselective OR antagonist naltrexone (5 mg/kg), the nonselective peripheral OR antagonist 
naloxone methiodide (5 mg/kg) or the selective 2 OR antagonist naltriben (0.3 mg/kg) 
completely abolished deltorphin II’s antiarrhythmic effect. But pretreatment with the 1-
selective antagonist BNTX (0.7 mg/kg) did not abrogate deltorphin II’s antiarrhythmic effect. 
Therefore, we concluded that peripheral 2 OR stimulation enhances cardiac tolerance to 
arrhythmogenic impact of ischemia and reperfusion. 245  
We found that intravenous administration of the 1 OR-selective peptide DPDPE at a 
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dose of 150 and 1500 nmol/kg had no effect on the incidence of ischemic and reperfusion 
ventricular arrhythmias in rats.245 Most of the opioid peptides poorly penetrate the 
BBB.23,24,209 We also tested the 1 OR-selective agonist TAN-67 and found that this opioid 
also was not antiarrhythmogenic.249 Therefore, we concluded that peripheral 1 OR agonists 
are not antiarrhythmogenic. However, Fryer et al. demonstrated an antiarrhythmic effect of 
TAN-67 in open-chest rats.102 Unlike our study, they gave TAN-67 at a dose 10 mg/kg (125 
fold higher the 0.08 mg/kg dose used by us). The higher dose would have penetrated the 
BBB. The antiarrhythmic effect of TAN-67 was no longer seen after selective blocking of  
OR.102 We suggest that the antiarrhythmic effect of TAN-67 is mediated via central OR 
stimulation. We conclude that peripheral 2 OR activation increases cardiac tolerance to the 
arrhythmogenic effect of ischemia/reperfusion while occupancy of the central 1 OR seems to 
have the same effect. 
C.  OR and arrhythmias from postinfarction cardiac fibrosis 
The picture is different with arrhythmias generated by postinfarction cardiac fibrosis. 
Intravenous administration of the selective 1 OR agonist DPDPE (0.1 mg/kg) increased the 
fibrillation threshold by 36 % in rats with postinfarction cardiac fibrosis.250 The 
antifibrillatory effect of DPDPE was lost after blockade of peripheral OR with naloxone 
methiodide or after selective inhibition of  OR with ICI 174,864. The selective 2 OR agonist 
DSLET (0.5 mg/kg) did not exert any antifibrillatory effect. In this study, we did not test 
selective 1 and 2 OR antagonists. Nevertheless, we suspect that the antiarrhythmic effect 
depended upon peripheral 1 OR stimulation.  
 
13. Controversy over  OR and arrhythmias 
In 1992, it was found that the selective  OR agonist U-50,488 (7.5 mg/kg, 
intravenously) enhanced cardiac tolerance to the arrhythmias from a 30-min coronary artery 
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occlusion. Because pretreatment with naloxone (2.5 mg/kg) did not eliminate U-50,488’s 
effect, these authors concluded that the protection was not dependent upon activation of  
OR.251 They proposed that the antiarrhythmic effect was caused by an off-target blockade of 
fast Na+ channels because after injection of U-50,488 they observed bradycardia and 
prolongation of the QRS duration (effects that are typical for I class antiarrhythmic drugs).251 
However, our results did not concur with these data. They gave U-50,488 at a dose of 7.5 
mg/kg and naloxone was administered at a dose of only 2.5 mg/kg, a dose which is not high 
enough for inhibition of  OR.198 We found that a lower dose of U-50,488 (1 mg/kg 
intravenously) prevents ventricular arrhythmias during coronary artery occlusion and 
reperfusion.252 We believe that the dose of U-50488 (7.5 mg/kg) used by Pugsley et al. was 
too high causing it to exhibit non-receptor effects.  
The above researchers tried to compare antiarrhythmic properties of the  OR agonist 
PD 129290 and its R,R (+)-enantiomer which has a low affinity to  OR.253 Both enantiomers 
at a dose of 3 mg/kg decreased arrhythmias from a 30-min coronary artery occlusion. Since, 
naloxone at a dose of 2.5 mg/kg did not abolish this effect, these authors concluded again that 
the antiarrhythmic effect of both enantiomers was independent of  OR. Furthermore, both 
enantiomers increased the QRS duration and in isolated cardiomyocytes, both compounds did 
inhibit Na+ current.253 They again concluded that the antiarrhythmic effect of these opioids is 
due to blocking Na+ channels. In a study with isolated cardiomyocytes, the same research 
group found that U-50488 and PD 129290 also inhibit Na+ current. The κ OR antagonist itself 
MR2266 did not produce any change in the Na+ or K+ currents, nor did it alter the channel 
blocking properties of U-50,488.254 The electrophysiological effects of U-50,488 were 
compared with those of the class Ib antiarrhythmic agent lidocaine in rat heart and the sodium 
currents expressed in Xenopus laevis oocytes by using two-electrode voltage clamp.255 Both 
U-50,488H and lidocaine produced a concentration-dependent tonic block of Na+ current but 
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U-50,488H was approximately 4 fold more potent than lidocaine. These authors maintain that 
the antiarrhythmic properties of the  OR agonists do not depend on OR activation and is an 
outcome of nonspecific Na+ channel blocking.253-255 
We continued the study using U-50488 enantiomers, which differ in affinity to 1 
OR.217 It appeared that (-)-trans-(1S,2S)-U-50,488 (1 mg/kg intravenously) with high affinity 
to 1 OR can reduce arrhythmias from 10 min of coronary artery occlusion and reperfusion in 
rats.252,256,257 An enantiomer (+)-trans-(1R,2R)-U-50,488 with low affinity to 1 OR did not 
exert similar effect. 252,256,257  Others have shown that the preferential 1 OR agonist dynorphin 
A1-13 at a dose of 40 μg/kg intravenously also exerts antiarrhythmic effect in cats with 
coronary artery occlusion.258 Furthermore, we established that pretreatment with the selective 
 OR antagonist nor-binaltorphimine (9 mg/kg, intravenously) completely abolished 
antiarrhythmic effect of (-)-U-50,488.256 Pretreatment with the 2 OR antagonist quadazocine 
(3 mg/kg, intravenously) did not alter antiarrhythmic effect of (-)-U-50,488.256 The selective 
2 OR agonist GR-89696 (25 μg/kg, intravenously) also had no effect on the reperfusion 
arrhythmias in rats.259 However, inhibition of peripheral ORs with naloxone methiodide (5 
mg/kg, intravenously) completely abolished antiarrhythmic effect of (-)-U-50,488.259 
Comparison of the above observations convinced us that peripheral 1 OR activation 
can enhance cardiac tolerance to ischemia/reperfusion-generated arrhythmias. The basis for 
this assertion are our data that the selective 2 OR agonist GR-89696 does not exhibit 
antiarrhythmic properties and that the 2 OR antagonist quadazocine did not abolish the 
antiarrhythmic effect of (-)-U-50,488.259 But pretreatment with naloxone methiodide or nor-
binaltorphimine does abolish the antiarrhythmic effect of (-)-U-50,488.259 At high 
concentration, (-)-U-50,488 clearly does block sodium channels. But at a low dose, the 
antiarrhythmic effect of U-50,488 is mediated via 1 OR occupancy alone.  
We determined that intravenous administration of the selective ORL1 agonist 
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nociceptin at a dose of 220 or 1500 nmol/kg had no effect on the incidence of ischemic and 
reperfusion-induced ventricular arrhythmias in vivo.245 However, nociceptin is not resistant to 
enzymatic hydrolysis. Therefore, we cannot completely exclude the possibility that a selective 
ORL1 agonist will exhibit antiarrhythmic properties.  
 
14. Arrhythmogenic and proarrhythmic effects of opioids  
It has been shown that injection of the non-selective OR agonist β-endorphin into 
perfusion solution caused only atria1 fibrillation and atrioventricular block in isolated rat 
heart.260,261 It should be noted that in vivo β-endorphin exhibits antiarrhythmic properties in 
anesthetized cats with coronary artery occlusion.262 In 1987, Lee and Wong demonstrated that 
injection of the preferential κ OR agonist dynorphin1-13 (20 μg/heart) caused both atrial and 
ventricular arrhythmias in isolated rat heart.263 This effect was antagonized by naloxone. In 
1990, Wong et al published results of their experiments on isolated Langendorff-perfused rat 
heart.264 The OR agonists and antagonists were injected directly into the aorta through 
cannulas. The OR antagonists were administered 1 min before the administration of OR 
agonist or 20 min global ischemia and 60 min reperfusion. The selective μ OR agonist 
DAMGO evoked atrial arrhythmias and at a higher dose caused frequent premature 
ventricular contractions (PVC).264 The selective κ OR agonist U50488 caused both atrial and 
ventricular arrhythmias. At a high dose (132 nmol/heart), this opioid induced frequent PVC 
and ventricular tachycardia. The δ OR agonists DPDPE and DADLE evoked only atrial 
arrhythmias. The arrhythmogenic effects of U50488 were attenuated by pretreatment with the 
κ OR antagonist MR 2266 in a dose-related manner whilst the proarrhythmic effect of 
DAMGO was abolished by the preferential μ OR antagonist naloxone. Naloxone itself 
exhibited a weak antiarrhythmic effect manifested in prevention of only ventricular 
tachycardia during reperfusion. Authors concluded that the cardiac κ OR are the most likely 
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receptors involved in arrhythmogenesis during ischemia and reperfusion.264 The limitation of 
this study was the fact that the bolus administration of opioids did not allow them to compare 
the concentrations of the opioids with their respective Kds and Kis. Consequently, this work 
does not allow evaluating the role of OR subtypes in the arrhythmogenic effects of opioids.  
MR 2266 also exhibits an antiarrhythmic effect. Therefore, the combined use of MR 
2266 and U50488 could eliminate the arrhythmogenic effect of U50488 regardless of OR 
blockade. Later it was shown that intravenous administration of dynorphin (300 nmol/kg) 
diminished the arrhythmogenic effect of coronary artery occlusion in rats.265 This effect was 
abolished by pretreatment with naloxone (1 mg/kg). However, since naloxone itself exhibits 
an antiarrhythmic effect, it remains unclear whether the inhibition of the proarrhythmic effect 
of dynorphin by naloxone occurred due to the blockade of ORs or the antiarrhythmic effect of 
naloxone overshadowed the proarrhythmic effect of dynorphin. Interestingly, according to 
others, dynorphin A1-13 (25 nmol/kg) prevents the occurrence of ventricular fibrillation in 
anesthetized cats subjected to occlusion of the left coronary artery.266 In 2003, Coles et al. 
published a comparative study of the cardiovascular effects of opioids in pigs with coronary 
artery occlusion (45 min) and reperfusion (3h).267 They found that the preferential δ OR 
agonist DADLE (1 mg/kg) and the preferential κ OR agonist pentazocine (5 mg/kg) 
aggravated the arrhythmogenic effect of coronary artery occlusion. The selective κ OR 
antagonist nor-binaltorphimine (1.5 mg/kg) exhibited the same effect. However, pretreatment 
with nor-binaltorphimine completely abolished the proarrhythmic effect of both DADLE and 
pentazocine. The authors concluded that κ OR activation during ischemia exhibits 
proarrhythmic effect in pigs.267 Indeed, it is known that DADLE can activate κ ORs in 
isolated hearts and we cannot exclude the possibility that its proarrhythmic effect is mediated 
by activation of these receptors.143 However, we would like to draw the readers’ attention to 
the following paradox: the κ OR antagonist nor-binaltorphimine also had a pro-arrhythmic 
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effect that disappeared when treatment with the κ OR antagonist was combined with the κ OR 
agonist during ischemia. It is worth mentioning that the authors used high doses of the OR 
agonists. Meanwhile it is well known that opioid peptides at high concentration may interact 
with non-ORs.268-270 Therefore, there is a possibility that the toxic effects of DALDA and 
pentazocine are unrelated to the ORs but mediated via stimulation of other receptors.  
It is worth mentioning that we have never observed an arrhythmogenic or 
proarrhythmic effect of opioids administered intravenously to rats or in the experiments on 
isolated perfused rat heart. We noticed a proarrhythmic effect of DADLE only in pigs during 
coronary artery occlusion at a high dose of 1 mg/kg.101 However, we do not exclude the 
possibility that opioids may have arrhythmogenic and proarrhythmic effects associated with 
the activation of central ORs when used at a high dose. We have established that the κ1 OR 
agonist U-50488, the κ OR agonist [D-Ala2]-Dynorphin A(1-13) and the preferential κ2 OR 
agonist (-)-bremazocine administered intracerebroventricularly potentiate the arrhythmogenic 
effect of intravenous epinephrine.271,272 The effect of U-50,488 was completely bl271,272 
Pretreatment with N-cholinergic receptor antagonist hexamethonium prevented proarrhythmic 
effects of the intracerebroventricular administration of U50488 and dynorphin.271 In contrast, 
intravenous administration of the preferential κ2 OR agonist (-)-bremazocine and 
intraperitoneal injection of the selective κ OR agonist spiradoline  blunted the arrhythmogenic 
impact of epinephrine.272 This effect was abolished by pretreatment with nor-binaltorphimine 
but not hexamethonium or atropine. These data indicate that stimulation of the central κ OR 
may promote a proarrhythmic effect mediated by the autonomic nervous system. Stimulation 
of peripheral κ OR may have an antiarrhythmic effect which is independent of the autonomic 
regulation of heart rhythm. 
Thus, we do not exclude the possibility that high doses of opioids may have 
proarrhythmic and arrhythmogenic effects in humans and animals associated with the 
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activation of non-ORs or activation of central κ ORs. There is also a possibility that activation 
of a cardiac κ OR subtype can also contribute to the appearance of ventricular arrhythmias. 
 
15. Antiarrhythmic actions of opioid antagonists 
There are reports that the OR antagonists can also exhibit antiarrhythmic properties 
during I/R of heart.273-277 These investigations showed that intravenous administration of 
naloxone (1 mg/kg) before coronary artery occlusion in anaesthetized dogs reduced the 
incidence and severity of cardiac arrhythmias during coronary artery occlusion and 
reperfusion.273 Studies also indicate that pretreatment with the κ2 OR antagonist quadazocine 
(3 mg/kg) or the OR antagonist (-)-Mr 1452 (4 mg/kg) prevents the appearance of arrhythmias 
induced by coronary artery occlusion in rats.274 These investigators established that naloxone 
(0.5 mg/kg), the preferential κ OR antagonist Mr 2266 (4 mg/kg), or the non selective OR 
antagonist MrZ 2593 (a quarternary complex of naloxone which does not readily cross the 
BBB at 1 mg/kg) all prevent the appearance of arrhythmias evoked with regional cardiac 
ischemia in rats.275 It has been reported that intravenous administration of the nonselective 
OR antagonist nalmephene (1 mg/kg) prevents reperfusion-induced arrhythmias in dogs.276 
There was also a report that pretreatment with naltrexone (2 mg/kg) or methylnaltrexone (2 
mg/kg), a quaternary derivative of naltrexone that does not cross the BBB, prevents 
ventricular fibrillation induced with coronary artery occlusion in rabbits.277 
Our studies found that the OR antagonists (naltrexone, naloxone methiodide, naltriben, 
BNTX, quadazocine, nor-binaltorphimine, CTAP, β-funaltrexamine, ICI-174,864) had no 
effect on the incidence of ventricular arrhythmias during coronary artery 
occlusion/reperfusion in rats.256,257,259 It is unclear why our data contradict the data of the 
other researchers. It should be noted that many of the aforementioned studies used antagonists 
(Mr 1452, Mr 2266, nalmephene, methylnaltrexone) which are no longer used in OR studies 
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because they exhibit OR independent effects. All our studies were performed with rats and 
perhaps there were also species differences in the response to the OR antagonist. The authors 
who found an antiarrhythmic effect of naloxone and naltrexone were performed in 
investigations with dogs and rabbits.273,277 The nonselective OR agonist pentazocine 
reportedly prevented the appearance of ventricular reperfusion arrhythmias in isolated rat 
hearts.231 
 
16. The effect of comorbidities on the cardiovascular effects of opioids  
Pathological processes may significantly change the cardiovascular system response to 
exogenous opioids. For example Bolte et al.278 found augmented negative inotropic and 
lusitropic response to administration of the selective δ OR, κ OR agonists in the failing 
hamster heart. However, Kasper et al. could not find any difference in the negative inotropic 
effect of κ OR agonist U-50,488H on control and cardiomyopathic hamster 
cardiomyocytes.279 The inhibitory action of the selective κ OR agonist U50 488H on β-
adrenoceptor augmentation of voltage-dependent [Ca2+]i transients in the isolated 
cardiomyocytes appeared to be significantly reduced in spontaneously hypertensive rats.280 In 
2001, Pei et al. demonstrated that the effect of U50,488H on the [Ca2+]i transient in the 
isolated cardiomyocytes was significantly attenuated due to right ventricular hypertrophy 
induced by chronic hypoxia.281 The authors established that κ OR signaling was impaired in 
the hypertrophied cardiomyocytes due to a defect in the coupling between κ OR and PKC. It 
was also found that high fat-induced obesity alters cardiovascular response to the 
administration of opioids in conscious rats.282  
The pathological process itself may change the state of the endogenous opioid system. 
It has been shown that cardiomyopathy evoked an increase of the preproenkephalin A mRNA 
level in ventricles of hamsters.283 In spontaneously hypertensive rats, the heart content of 
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dynorphin A was increased by 6.5-fold compared to Wistar rats.284 Plasma β-endorphin levels 
are also elevated in dogs with pacing-induced congestive heart failure. Naloxone injection 
increased heart rate, mean aortic pressure, first derivative of left ventricular pressure and 
cardiac output in these dogs while in the intact animals, naloxone did not affect the 
hemodynamics.285 These data suggest the involvement of endogenous opioids in the 
pathogenesis of pacing-induced congestive heart failure. This hypothesis can be supported by 
the data of Imai et al.286 They found that not only naloxone but also the selective δ OR 
antagonist ICI-154,129 increased mean aortic pressure, cardiac output and positive first 
derivative of left ventricular pressure in dogs with artificially induced right heart failure. 
Constriction of the aorta induced an elevation of β-endorphin level in blood plasma of rats.287 
In 1995, Oldroyd et al. found that plasma β-endorphin was increase by 29% in patients with 
acute heart failure and by 71% in patients with cardiogenic shock.288 However, the level of 
this opioid in plasma was decreased in spontaneously hypertensive hamsters.389 It was 
demonstrated that the decrease in left ventricular systolic pressure after administration of the 
κ OR agonist U50488H was attenuated in these hamsters. 
These results show that pathological process can exert a significant effect on the 
endogenous opioid system. Can the accompanying pathological process change the 
cardioprotective effect of opioids? It has been demonstrated that aging does not alter a 
cardioprotective effect of BW373U86, a selective δ OR agonist.168 However, in 2007, Peart et 
al. reported that the selective δ OR agonist DPDPE only improves contractile recovery after 
reperfusion of isolated mouse hearts from young animals.228 They found that aging-related 
loss of δ-opioid-mediated cardioprotection involves failure to activate p38 MAPK (mitogen 
activated protein kinase) and HSP27 (heat shock proteins). Gross’s group demonstrated that 
morphine did not limit the infarct size in rats with streptozotocin-induced diabetes. This lack 
of protective effect was associated with the loss of coupling between ORs and glycogen 
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synthase kinase 3β (GSK-3β).290 It was also shown that remifentanil reduced myocardial 
infarct size and prevented apoptosis of cardiomyocytes evoked by ischemia/reperfusion in 
non-diabetic rats but not in rats with streptozotocin-induced diabetes.89 Gross’s group’s data 
were confirmed by Chen et al.199 They demonstrated that sufentanil reduced myocardial 
infarct size in the non-diabetic rats, but not those with streptozotocin-induced diabetes. The 
GSK-3β inhibitor SB216763 reduced infarct size in both non-diabetic and diabetic rats. The 
authors concluded that absence of opioid-induced tolerance of rat heart to reperfusion injury 
in diabetic animals is the result of impaired interaction of ORs and GSK-3β.199  
The results of these studies cannot be mechanically applied to the humans because the 
most common form of diabetes in humans is a type 2 diabetes mellitus characterized by 
insulin resistance. Streptozotocin causes damage to the β cells of Langerhans islets and leads 
to decreased insulin secretion. Therefore streptozotocin-induced diabetes is most similar to 
insulin-dependent type 1 diabetes mellitus in humans.  However, Tsang et al. showed in 
experiments using a rat model of type 2 diabetes mellitus (Goto-Kakizaki rats) that diabetes 
depresses the PI3K/Akt pathway during IP causing loss of protection. But the elevated 
threshold for Akt phosphorylation and protection can be reached by simply increasing the 
number of IP cycles.291 Since this same signaling pathway is involved in the protective 
mechanism of opioids, as we discuss in the subsection “Signaling Mechanism of the 
Cardioprotective Effect of Opioids” above, it seems likely that an increasing the dose of an 
OR agonist may still be able to protect the diabetic heart against I/R injury. Taken together, 
the presented data suggest that diabetes and age may undermine the efficacy of opioid-
induced cardioprotective effects. It remains unknown whether atherosclerosis, arterial and 
pulmonary hypertension, myocardial hypertrophy or heart failure might also alter their 
protection. The phenomenon of heart resistance to cardioprotective stimuli due to co-morbid 
diseases is potentially a serious problem in the translation of cardioprotective interventions to 
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clinical practice.292 However, this problem may be solved by either increasing the stimulus or 
by direct activation of the downstream components of the signaling pathways such as p38 
MAPK/HSP27 or inhibition of GSK-3β, which remain relatively intact in these conditions.  
 
17. Prospects for the use of opioid receptor agonists in cardiological practice  
It has been found that the chronic administration of morphine increases cardiac 
tolerance to ischemia and reperfusion.293-297 The signaling mechanism of the cardioprotective 
effect of chronic morphine administration differs from that of acute administration of 
morphine.296 Chronic κ-OR stimulation prevents isoprenaline-induced cardiac hypertrophy 
and fibrosis.298 Unfortunately, morphine and heroin in chronic administration cause rapid 
formation of drug dependence.299 The formation of opioid dependence is associated with 
activation of central μ OR.300 The ability to form a dependence is much less pronounced in the 
δ OR or κ OR agonists.300 Therefore, δ OR and κ OR agonists are not on the DEA controlled 
substances list. However, since the κ OR agonists cause dysphoria, their indication for chronic 
use is also unlikely.301 In our opinion, the most promising agents for chronic use are peptide 
OR agonists, that poorly penetrate the blood-brain barrier.22,23,24 These include the selective μ 
OR agonist DALDA (NH2-Tyr-D-Arg-Phe-Lys-NH2)
227 and non-selective μ OR and δ OR 
agonist dalargin (H-Tyr-D-Ala-Gly-Phe-Leu-Arg-OH).302 Our experiments have shown that 
dalargin exhibits antifibrillatory properties.239 In Russia, this drug is used to treat stomach 
ulcers.303 We have shown that a quaternary analogue of the κ opioid agonist U-50488 is 
another opioid that does not penetrate the BBB and is capable of increasing cardiac tolerance 
to ischemia/reperfusion.123 Therefore, we suggest that those opioids, which are not able to 
activate the central ORs after systemic administration might be most amenable to chronic use 
as cardioprotectants in high risk cases. 
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Based on the data accumulated by our and Gross’s group,129 the most promising 
compounds for development of drugs, which acutely increase the heart’s tolerance to the 
detrimental effects of ischemia and reperfusion are deltorphin II, ICI 199,441 and Eribis 
peptide 94. Following clinical trials, these compounds or their analogs may find use in the 
treatment of acute myocardial infarction or in surgergical patients receiving coronary bypass. 
 
18. Signaling Mechanism of the Cardioprotective Effect of Opioids  
The data described below are summarized in the signaling scheme for the 
cardioprotective effect of opioids presented in Figure 1. The phenomenon of ischemic 
preconditioning was found to be triggered by activation of Gi/o-coupled adenosine receptors 
that activate PKC and ultimately protects by inhibiting MPT early in reperfusion.304  Soon it 
was discovered that bradykinin and OR act in parallel with the adenosine receptors as all 3 are 
populated during a preconditioning ischemia. Occupation of any one receptor type can put the 
heart into a conditioned state. It is hypothesized that ORs couple with Gi/o proteins which then 
inhibit adenylyl cyclase and activate phospholipase C which, in turn, synthesizes 
diacylglycerols stimulating protein kinase C.248 Therefore, investigators have attempted to 
determine if the cardioprotective effect of opioids is associated with Gi/o protein activation. In 
a study with rats, it was shown that the Gi/o protein inhibitor pertussis toxin eliminated the 
infarct reducing effect of the δ1 OR agonist TAN-67.91 Later experiments with isolated 
perfused murine heart demonstrated that pertussis toxin, which rybosylates the αi subunit of 
the Gi/o protein, eliminated the cardioprotective effect of morphine.
296 Currently it is 
hypothesized that Gi/o proteins serve as an intermediary link between OR and the protein 
kinases which perform the protective signaling. 
 
A. OR Protect Through PKC 
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In 1998, a study with isolated perfused rabbit heart it was shown that the protein 
kinase C (PKC) inhibitor chelerythrine abolishes the infarct sparing effect of morphine.81 In 
the following investigation performed with the isolated perfused rat heart it was found that 
pretreatment with chelerythrine eliminates the cardioprotective effects evoked by δ and κ1 OR 
in vitro stimulation.95,105,173,215 
In 2001, Gross’s group sought to identify which PKC isoforms are involved in the 
infarct limiting effect of opioids.305 They established that the cardioprotective effect of TAN-
67 and DADLE did not occur after inhibition of all PKCs with chelerythrine and after 
pretreatment with the selective PKC-δ inhibitor rottlerin. They concluded that the 
cardioprotective effect of δ OR agonists is mediated via PKC-δ activation. This result 
surprised us because PKC δ activation and translocation to mitochondria also promotes 
cardiomyocyte apoptosis306 and inhibition of PKC δ enhances cardiac tolerance to reperfusion 
injury.307  Also preconditioning’s protection of adult rabbit cardiomyocytes could be blocked 
by a PKC ε-specific antagonist but not one for PKC δ.308 However, more recent studied 
revealed that rottlerin is not a specific PKC-δ inhibitor.309 The key role of PKC in signaling 
mechanism of anti-necrotic effect of opioids was confirmed in later works.110,296,310  
In a 2001 study, isolated cardiomyocytes were assessed for apoptosis after exposing 
the cells to to hypoxia (12 hr) and reoxygenation (12 hr). This study indicated that the 
selective δ agonist BW373U86 prevented apoptosis of cardiomyocytes. Pretreatment with Go-
6976, an inhibitor PKC-α and PKC-β, abolished this protective effect of BW373U86.158 This 
study showed the anti-apoptotic effect of the δ OR agonist can be attributed to PKC-α and 
PKC-β activation. 
A number of studies have demonstrated that PKC is involved in the antinecrotic and 
antiapoptotic effects of opioids. Debate still revolves around the question of which PKC 
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isoforms are involved in the opioid-induced enhancement of cardiac tolerance to 
ischemia/reperfusion.  
 
B. PI3 kinase, Akt, and MAPK- the RISK Pathway 
Another set of kinases shown to be in the conditioning pathway are PI3 kinase, Akt 
and p42/p44 MAPK. These kinases are collectively called the Reperfusion Injury Survival 
Kinase (RISK) pathway and are downstream of PKC and are involved in mediating the 
protection early in reperfusion.311 Isolated rabbit cardiomyocytes were subjected to hypoxia 
and reoxygenation and the endogenous μ and δ OR agonist met-enkephalin reduced 
cardiomyocytes death. Pretreatment with the PI3 kinase inhibitor LY-294002 abolished the 
cytoprotective effect.312 We have found that intravenous U-50,488 decreases the IS/AAR in 
rats with coronary artery occlusion and the PI3 kinase inhibitor wortmannin abolished the 
infarct sparing effect.313 PI3 Kinase phosphorylates membrane phosphoninositide at the 3 
position and this product activates phosphoinositide-dependent kinases (PDKs) which 
activates Akt by phosporylating it. Recently, it has been shown that the infarct limiting effect 
of sufentanil in vivo also was abolished by pretreatment with wortmannin.314 
Gross’s group found that intravenous administration of morphine (0.3 mg/kg) in rats 
induces an increase in the phosphorylation of cardiac Akt early in reperfusion.108,116 The same 
group utilizing an isolated murine heart found that DPDPE evoked phosphorylation of Akt.228 
These data were confirmed by Huang et al.52 It was also shown that the phosphorylation of 
Akt was involved in the cardioprotective effect of remifentanil162 and morphine.315 Based on 
the aforementioned studies it appears that PI3 kinase and Akt are involved in cardioprotective 
effect of opioids. 
Mitogen activated protein kinases (MAPK) comprise a family of kinases involved in 
growth and cytoprotection. They include p38 MAPK, JNK, p42 MAPK and p44 MAPK. The 
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last two isoforms are also known as Extracellular Receptor Kinase (ERK). Like all MAPKs, 
ERK1/2 are activated by two upstream kinase kinases, MEK1/2 which can be inhibited by PD 
098059.  PD 098059 completely abolishes the anti-infarct effect of TAN-67. Furthermore, 
TAN-67 increased the phosphorylation ERKs during reperfusion and this was prevented by 
PD 098059.316 Ikeda and colleagues found that intravenous administration of the δ OR agonist 
DADLE (1 mg/kg) increased the phosphorylation of both isoforms of ERK in the 
myocardium.94 PD 098059 abolished both ERK’s phosphorylation and the protection. Van 
Winkle’s group published a study where isolated rabbit cardiomyocytes subjected to hypoxia 
and reoxygenation were protected with met-enkephaline and experienced increased 
phosphorylation of ERK1/2. Pretreatment with PD 098059 or the selective MEK1/2 inhibitor 
U-0126 abolished both effects.312 The anti-infarct effect of U50488H could be blocked by an 
ERK inhibitor but not by one for the PI3K-Akt pathway.317  Ha and colleagues also found that 
the non-selective OR agonist remifentanil before reperfusion promotes an increase in the 
phosphorylation of ERK1/2 which could be reversed by naloxone or by a non-selective 
adenosine receptor inhibitor.200 The A2b adenosine receptor has been proposed to be 
upstream of ERK in the preconditioning pathway.304  
 
C. Other protective kinases 
In 2011, a study by Li et al. indicated that morphine can ameliorate myocardial 
contractile dysfunction and limit infarct size following ischemia and reperfusion by a 
mechanism involving activation of AMPK (AMP-activated protein kinase).161 
JNK and P38 MAPK are also members of the MAPK family that have been implicated 
in cardioprotection. Despite an increase in phosphorylation of both p38 MAPK and JNK by 
TAN 67, its cardioprotective effect could not be blocked by the p38 MAPK inhibitor SB-
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203580.203.228,305 Other groups also find an increased phosphorylation of p38 MAPK after 
morphine use.189,318   
Morphine induces phosphorylation of GSK-3β and JAK2.116,290 Phosphorylation of 
GSK-3β has been proposed to directly inhibit the opening of MPT and is currently regarded 
as a critical component in the conditioning pathway.304 Phosphorylation of GSK-3β inhibits 
its kinase activity and the GSK-3β inhibitor SB-216763 mimicks morphine’s protection. 
Morphine’s protection is lost after inhibition of JAK2. JAK2 is a member of the SAFE 
pathway has been implicated in the mechanism of the heart’s conditioning phenomenon .304 It 
is unclear whether JAK directly phosphorylates GSK-3β kinase or acts indirectly through 
other kinases. DPDPE contributes to phosphorylation p70S6 kinase and GRK2 in isolated rat 
heart228 however, it is not known whether these effects have any relevance to its protective 
effect.  
The endothelial nitric oxide synthase (eNOS) has been implicated in the 
preconditioning’s trigger pathway between Gi/o coupled receptors and PKC.304 We have found 
that the infarct sparing and antiarrhythmic effects of deltorphin II disappears after 
pretreatment with the eNOS inhibitor L-NAME.117 We have shown that pretreatment with L-
NAME abolished the infarct reducing effect of U-50,488.313 In a study of the cardioprotective 
effect of Eribis peptide 94 similar data were noted by Gross et al.129 
 
D. Tyrosine kinases 
The kinases discussed above phosphorylate serines or threonines in their target 
proteins. Another family of kinases only phosphorylate tyrosine residues. Tyrosine kinases 
are proposed to be involved in the transactivation of the epidermal growth factor (EGF) 
receptor, a step in the OR’s trigger pathway for preconditioning.304  A 2001 study indicated 
that the nonselective tyrosine kinase genistein completely abolished the infarct sparing effect 
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of TAN-67 and DADLE but lavendustin, an inhibitor of Src kinase and the EGF receptor, did 
not affect the cardioprotective effect of TAN-67 or DADLE.305 These investigators concluded 
that neither Src kinase nor the EGF receptor are involved in the cardioprotective effect of δ 
agonists but that some tyrosine kinase is involved. Quite the opposite findings were obtained 
by Cao and colleagues.312 They subjected isolated cardiomyocytes to hypoxia and 
reoxygenation and the Src kinase inhibitor herbimycin A completely abolished the 
cytoprotective effect of met-enkephalin. Finally, we have also shown that the infarct limiting 
effect of deltorphin II is maintained after pretreatment with genistein.117 
Studies have shown that the infarct sparing effect of morphine and δ agonist FIT 
disappeared after pretreatment with AG-490, an inhibitor of the tyrosine kinase JAK2, but not 
with the JAK3 inhibitor ZM-449829.116 Morphine induced phosphorylation of JAK2 in the 
area at risk.116,290 It is possible that JAK2 may be the tyrosine kinase which is involved in 
opioid induced enhancement of cardiac tolerance to ischemia/reperfusion. 
E. Interactions between adenosine receptors and ORs  
Isolated perfused rat hearts were subjected to ischemia/reperfusion and fentanyl 
improved the post ischemic recovery. Naloxone abolished the protection from fentanyl as did 
the selective adenosine A1 receptor antagonist DPCPX.
214 These authors concluded that the 
protective effect of fentanyl involved both ORs and the A1 receptor. Similar data were 
obtained by Peart and Gross, they administered either morphine or the selective adenosine A1 
receptor agonist CCPA to rats to rats subjected to coronary artery occlusion and either 
compound evoked a decrease in the IS/AAR. The infarct limiting effect of morphine was 
eliminated by DPCPX and after selective blocking δ1 OR with BNTX. Furthermore, the 
cardioprotective effect of CCPA was blocked after injection of either DPCPX or BNTX.320 
Coadministration of morphine and CCPA did not offer any additive protection. These authors 
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concluded that there is an interaction between δ1 OR and A1 receptor at the intracellular 
signaling level (cross-talk).  
F. Transactivation of the EGF receptor 
In 2005, Gross’s group published data on the cardioprotective effect of endogenous 
adenosine.321 The level of adenosine was elevated with intravenous administration the 
adenosine kinase inhibitor 5-iodotubercidin (1 mg/kg). This compound decreased the IS/AAR 
2 fold. Pretreatment with the adenosine A1 receptor-selective antagonist DPCPX, the 
adenosine A3 receptor-selective antagonist MRS-1523 or the δ1 OR-selective antagonist 
BNTX abolished the infarct reducing effect of 5-iodotubercidin.321 These data led these 
researchers to conclude that the cardioprotective effect of endogenous adenosine is mediated 
via simultaneous A1 receptor, A3 receptor and δ1 OR activation. Recently, Ha et al. found that 
the non-selective OR agonist remifentanil started 5 min before reperfusion in the isolated rat 
heart decreases the IS/AAR and evokes the phosphorylation of ERK1/2. These effects were 
blocked by pretreatment with naloxone or the non-selective adenosine receptor antagonist 8-
(p-sulfophenyl) theophylline.200 It is our opinion that the aforementioned studies provide 
evidence of interaction of adenosine and OR at some level. It has been proposed that 
transactivation may be involved as both receptors converge through transactivation of the 
EGF receptor.322,323 However, it is not clear how inhibition of one could turn off signaling of 
the other through this transactivation.  
EGF receptor activation protects against ischemia/reperfusion.312,324,325 Met-
enkephalin reduces cell death in isolated cardiomyocytes subjected hypoxia and 
reoxygenation and phosphorylates the EGF receptor. The EGF tyrosine kinase inhibitor AG-
1478, the Src kinase inhibitor herbimycin A or naloxone eliminated phosphorylation of EGF 
receptor and the cytoprotective effect.312 
59 
 
Cardioprotective Properties of Opioid Receptor Agonists 
The aforementioned data indicate that there is an important role of transactivation of 
opioid and adenosine receptors in cardiac tolerance to impact of ischemia and reperfusion. 
Opioid transactivation of EGF receptor tyrosine kinase is a binder link between ORs and 
ERK1/2 and the downstream signaling pathways including ERK and PI3 kinase. The opinion 
EGF receptor transactivation is an important mechanism in implementing the protective effect 
of opioids is now shared by other physiologists.322,323 
G. KATP and BK channels 
Pretreatment with the KATP channel blocker glibenclamide abolished anti-infarct effect 
of morphine.10 Two years later the same group demonstrated that glibenclamide abolished the 
infarct reducing effect of TAN-67.91 It was also shown that the cardioprotective effect of 
DADLE in vitro disappeared after KATP channel blockade with this inhibitor.
92 Further studies 
were designed to determine what types of KATP channels are involved in cardioprotective 
effect of opioids. It was observed that incubation of cardiomyocytes with morphine prevents 
cell death and the selective inhibitor of the mitochondrial KATP channel (mitoKATP) 5-
hydroxydecanoate (5-HD) completely abolished the cytoprotective effect of morphine.82 
Pretreatment with fentanyl improved post-ischemic recovery of function and that was also 
dependent on the opening of mitoKATP.
214 In 2000, it was found the antiarrhythmic and infarct 
sparing effect of TAN-67 in vivo was abolished by blocking mitoKATP with 5-HD  but not 
after blocking sarcolemmal KATP channels (sarcKATP) with HMR 1098.
102 The cytoprotective 
effect of TAN-67 in isolated cardiomyocytes disappeared after blocking mitoKATP with 5-
HD.105 5-HD also blocked the cardioprotective effect of U-50,488 in isolated perfused rat 
heart,326 abolished the cytoprotective effect of morphine and δ agonist BW373U86 in isolated 
chicken cardiomyocytes.107 In an in vivo study we found that the infarct reducing effect of 
deltorphin II did not occur after blockade of mitoKATP with 5-HD.
117 A large number of 
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similar publications now confirm the key role of mitoKATP in the cardioprotective effect of 
opioids.  
A few studies also show a role of sarcKATP in opioid-induced cardioprotection. The 
cytoprotective effect of met-enkephalin disappeared after selective blockade of mitoKATP with 
5-HD or after selective blockade of sarcKATP with HMR 1098.
98,99 The anti-infarct effect of 
morphine and BW373U86 in vivo was no longer observed after either mitoKATP or sarcKATP 
blockade.108 In another study it was demonstrated the cardioprotective effect of Eribis peptide 
94 was dependant on both mitoKATP and sarcKATP opening.
129 
In 2005, it was proposed that the mitochondrial Ca2+-dependent big conductance K+ 
channel (mitoBKCa channel) was involved in the cardioprotective mechanism of opioids. The 
κ1 OR agonist U-50,488 provided a decrease in the IS/AAR in isolated rat heart and prevented 
cell death isolated myocytes subjected to simulated ischemia/reperfusion. The mitoBKCa 
channel inhibitor paxilline abolished both effects of U-50488.327 
H. Redox signaling 
The above studies indicate that mitoKATP and perhaps sarcKATP are involved in the 
cardioprotective effect of opioids. It was originally thought that KATP must be end effectors of 
the protection, however, evidence now indicates that their role is primarily one of signal 
transduction. Studies with preconditioning provided strong evidence that opening of mitoKATP 
activate PKC through redox signaling with free radicals304 and that seems to include signaling 
from the ORs.  The anti-infarct effect of morphine in rabbit heart could be blocked with the 
free radical scavenger N-2-mercaptopropionyl glycine (MPG).328 10 min preconditioning with 
morphine or BW373U86 increased cell survival of isolated chicken cardiomyocytes subjected 
to hypoxia and reoxygenation. Morphine-induced protection and free radical production was 
abolished by MPG, naloxone, BNTX, a selective δ1 OR antagonist; or 5-HD. The superoxide 
dismutase inhibitor diethyldithiocarbamic acid exhibited the same effect. Finally the increase 
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in oxygen radicals was abolished by the mitochondrial electron transport inhibitor 
myxothiazol.329 It was also shown later that the infarct sparing effect of morphine does not 
occur after blocking ROS production with MPG.320 In a study with isolated cardiomyocytes 
subjected to hypoxia/reoxygenation, it was shown that the cytoprotective effect of morphine 
disappeared after pretreatment with MPG.315 
Thus, the above data indicate that opioid induced opening of mitoKATP leads to 
increased production of ROS which through redox signaling enhances of cardiac tolerance to 
ischemia/reperfusion. 
I.  MPT 
Elevated cytosolic ROS and Ca2+ in the first minutes of reperfusion are thought to 
open MPT (mitochondrial permeability transition pores).156 MPT can destroy the 
mitochondria and either kill the cardiomyocyte outright (necrosis) or release proapoptotic 
substances depending on how may mitochondria are lost. A 2005 study indicated that MPT 
are involved in the cardioprotective effect of opioids.327 The regional ischemia and 
reperfusion was carried out in the isolated perfused rat heart. U-50488 decrease in the 
IS/AAR and lactate dehydrogenase in the coronary effluent of isolated hearts. The MPT 
opener atractyloside abolished the cardioprotective effect of U-50488.327 It is assumed that 
OR stimulation inhibited MPT opening at reperfusion and opening MPT directly with 
atractyloside overrode any inhibition from protective signaling. Mitochondria isolated from 
the ischemic zone of rat hearts receiving morphine have an elevated threshold for opening 
MPT with Ca2+ and this resistance to MPT opening was lost if PI3 kinase was inhibited with 
wortmannin.330 In our in vivo study we demonstrated that U-50,488 induces an infarct 
reducing effect as well as an antiapoptotic effect. It also decreases the activity of caspases 
which become activated after MPT opening.163 The infarct sparing and antiapoptotic effects 
disappeared after blockade of mitoKATP with 5-HD. U-50,488 evoked an enhancement of 
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expression of antiapoptotic protein Bcl-2 and decreased the expression of proapoptotic protein 
Bax.163 Presumably, the κ1 OR agonist prevented MPT opening with signaling through 
mitoKATP as discussed above. Kim et al. also found that remifentanil not only limits infarction 
but also increased Bcl-2 and decreased Bax.89 We conclude that the current evidence indicates 
that the end effector of the cardioprotective effect of opioids is inhibition of the MPT early in 
reperfusion. 
 
19. Will an OR agonist provide protection to today’s patient population? 
The ORs appear to protect through a signaling pathway similar if not identical to that 
of IP and IPost. Evidence suggests that the loading doses of P2Y12 receptor inhibitors that are 
now routinely given to all patients undergoing reperfusion therapy to prevent platelet 
aggregation in their stents may also trigger this same protection could make the OR agonist 
redundant. The P2Y12 blocker cangrelor limited infarct size when present at reperfusion in 
open-chest rabbits by an amount similar to that with IPost. Protection from cangrelor could be 
blocked by 5-HD, wortmannin, adenosine receptor inhibitors, an ERK inhibitor, or the 
antioxidant N-2-mercaptopropionyl glycine. These same signaling inhibitors will block 
protection from both IP and IPost. None of those agents restored the ability of platelets to 
aggregate indicating that protective signaling rather that prevention of thrombi was 
responsible for the protection. When cangrelor and IPost were combined in rabbits, IPost 
caused no additional protection, probably because both protect by the same mechanism.331  
Recent attempts to translate IPost to clinical practice in the setting of acute myocardial 
infarction have been disappointing. The first IPost trial was performed just before P2Y12 
blockers came into widespread use and was very positive but all of those performed thereafter 
had P2Y12 blockers present in all patients and showed minimal or no protection from adding 
IPost.332 These data indicate that all of today’s patients receiving primary angioplasty to 
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reperfuse their coronary arteries are already in a postconditioned state from their P2Y12 
blocker loading dose. These drugs were quickly added to the guidelines because they greatly 
improved clinical outcomes. Their benefit was assumed to result from preventing 
intracoronary thrombi and the possibility of a direct anti-infarct effect was not considered. Of 
course today it would be impossible to do a clinical trial to measure their ability to reduce 
infarct size in man because it would be unethical to deny platelet inhibitors to a control group. 
Any clinically effective agent today must, therefore, be able to provide additional protection 
when combined with a P2Y12 inhibitor. To date no OR agonists have been tested to see if any 
of them can provide additional protection in an animal model treated with a P2Y12 inhibitor. 
That screening should be done before considering a large scale clinical trial of any 
cardioprotectant. 
 
20. Concluding Remarks 
Stimulation of central μ OR promotes reduction of infarct size during coronary artery 
occlusion and reperfusion. Occupancy of peripheral μ OR by opioids promotes better 
recovery of cardiac contractile function after ischemia. Activation of peripheral and possibly 
central δ1 ORs prevents cardiomyocyte necrosis, apoptosis and arrhythmias caused by 
ischemia/reperfusion of the heart. Stimulation of peripheral OR δ2 reduces infarct size and 
inhibits arrhythmogenesis during coronary artery occlusion and reperfusion. Activation of 
peripheral κ1 ORs also prevents cardiomyocyte necrosis, apoptosis and arrhythmias induced 
by ischemia/reperfusion. Stimulation of peripheral δ and κ ORs contributes to increase in 
cardiac contractility during reperfusion. No data are available on the involvement of ORL1 
receptor in the increased cardiac tolerance to ischemia/reperfusion by opioids. It should be 
noted however, that at high dose opioids may contribute to cardiac arrhythmias and this effect 
is probably mediated by non-opioid receptor activation. 
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The data show that the μ, δ1, δ2 and κ1 OR agonists all are promising candidates for a 
drug, which would enhance the cardiac tolerance to I/R. The OR agonists exert infarct-
reducing effects both with prophylactic administration and with acute treatment just prior to 
reperfusion. Furthermore, opioids are also effective in preventing ischemia-induced 
arrhythmias.  
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